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ABSTRACT 
Biodegradable Branched Polycationic Polymers as 
Non-viral Gene Delivery Vectors for Bone Tissue Engineering 
by 
Sue Anne Chew 
In this work, biodegradable branched triacrylate/amine polycationic polymers 
(TAPPs) were synthesized from different amine and triacrylate monomers by Michael 
addition polymerization and incorporated into a composite scaffold to evaluate these 
polymers in a bone tissue engineering system. The effects of the hydrophilic spacer 
lengths in the polymer on characteristics which are important for gene delivery were 
evaluated by varying the triacrylate monomer used in the synthesis. The results 
demonstrated that hydrophilic spacers can be incorporated into polycationic polymers to 
reduce their cytotoxicity and enhance their degradability. The effects of amine basicities 
in the polymer on characteristics which are important for gene delivery were also 
evaluated by varying the amine monomers used in the synthesis. The results indicated 
that polycationic polymers with amines that dissociate above pH 7.4, which are available 
as positively charged groups for plasmid DNA (pDNA) complexation at pH 7.4, can be 
synthesized to produce stable polyplexes with increased zeta potential and decreased 
hydrodynamic size that efficiently transfect cells. TAPP/pDNA polyplexes were then 
incorporated into a composite containing gelatin microparticles (GMPs) and a porous 
poly(propylene fumarate) scaffold. The release of pDNA in vitro was not affected by the 
crosslinking density of the GMPs but depended, instead, on the degradation rates of the 
TAPPs. Besides the initial burst release of polyplexes not bounded to the GMPs and the 
minimal release of pDNA through diffusion and dissociation from the GMPs, the pDNA 
was likely released as naked pDNA or in an incomplete polyplex as fragments of the 
polymer had to degrade to release the pDNA. The results indicated that polymeric vectors 
with a lower degradation rate can prolong the release of pDNA from the composite 
scaffold. Composite scaffolds loaded with TAPP/pDNA polyplexes may not have 
delivered enough intact polyplexes, as enhanced bone formation was not observed in a 
critical-size rat cranial defect at 12 weeks postimplantation compared to those loaded 
with naked pDNA. A gene delivery system consisting of biodegradable polycationic 
polymers should be designed to release the pDNA in an intact polyplex form. 
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CHAPTER I 
OBJECTIVE AND SPECIFIC AIMS 
The overall objective of this research is to synthesize and evaluate biodegradable 
branched polycationic polymers with different hydrophilic spacer lengths and amine 
basicities for non-viral gene delivery and to incorporate these polymers into a composite 
scaffold carrier to investigate them in a bone tissue engineering system. 
1. Synthesis and Characterization of Biodegradable Branched Triacrylate/Amine 
Polycationic Polymers with Varying Hydrophilic Spacer Lengths as Non-Viral 
Gene Delivery Vectors 
Synthesis of biodegradable branched triacrylate/amine polycationic polymers 
with varying hydrophilic spacer lengths by altering the triacrylate monomer 
used in the synthesis. 
Evaluation of the effects of the hydrophilic spacer lengths on characteristics 
of the polymer which are important for gene delivery (i.e., molecular weight, 
amine equivalents dissociating within different pH ranges, degradability and 
cytotoxicity). 
Evaluation of the effects of the hydrophilic spacer lengths on characteristics 
of the polymer and plasmid DNA polyplexes which are important for gene 
delivery (i.e., polyplex diameter, zetapotential and transfection efficiency). 
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2. Synthesis and Characterization of Biodegradable Branched Triacrylate/Amine 
Polycationic Polymers with Varying Amine Basicities as Non-Viral Gene 
Delivery Vectors 
Synthesis of biodegradable branched triacrylate/amine polycationic polymers 
with varying amine basicities by altering the amine monomer(s) used in the 
synthesis. 
Evaluation of the effects of the amine basicities on characteristics of the 
polymer which are important for gene delivery (i.e., molecular weight, amine 
equivalents dissociating within different pH ranges, degradability and 
cytotoxicity). 
Evaluation of the effects of the amine basicities on characteristics of the 
polymer and plasmid DNA polyplexes which are important for gene delivery 
(i.e., polyplex diameter, zetapotential and transfection efficiency). 
3. Fabrication and Evaluation of Composites Containing Triacrylate/Amine 
Polycationic Polymers andpDNA Polyplexes, Acidic Gelatin Microparticles and 
a Porous Poly(propylene fumarate) Scaffold for Bone Tissue Engineering 
Fabrication of composite scaffolds containing triacrylate/amine polycationic 
polymers and gelatin microparticles with different degradation rates. 
Evaluation of the effects of the triacrylate/amine polycationic polymers and 
gelatin microparticles degradation rates on the pDNA release kinetics in vitro. 
Evaluation of the ability of the composite scaffolds to enhance bone formation 
in a critical-size rat cranial defect in vivo. 
3 
CHAPTER II 
INTRODUCTION: NON-VIRAL GENE DELIVERY FOR BONE TISSUE ENGINEERING 
Abstract 
Aid is usually needed to repair bone defects with a large amount of bone loss or 
insufficient vascularity. Using a bone tissue engineering system that delivers a bioactive 
factor is a promising approach to repair such bone defects. Bone morphogenetic protein 
(BMP) is a bioactive factor that is capable of enhancing bone formation. Instead of 
delivering BMP in the protein form, BMP can also be delivered via gene therapy as a 
DNA encoding the BMP. There are a lot of barriers associated with the delivery of DNA 
in vivo. However, a vector such as a polycationic polymer can be used to help overcome 
some of these barriers. In addition to the polycationic polymer vector, the carrier that will 
be used to deliver the vector/DNA complexes is also an important factor that should be 
taken into consideration and incorporated when designing a successful gene delivery 
system for bone tissue engineering. 
Bone 
Bone Anatomy 
Bone is a connective tissue that is firm and has sufficient strength to bear load. 
Bone forms the skeleton of the body and provides sites for the attachment of muscles. 
Bone also functions to protect certain organs in the body such as the brain, heart and 
lungs, and is a source of calcium, phosphate and other minerals. Bone is made out of an 
4 
organic phase that consists of mostly collagen type 1 and an inorganic phase1 that consists 
of about 30% amorphous calcium phosphate and a little less than 70% crystalline 
hydroxyapatite2. Bone is also made out of a cellular element which consists of osteoblasts, 
osteocytes and osteoclasts. 
Bone can be divided into two morphological types, cortical or cancellous bone. 
Cortical bone, which is also known as compact bone, is very dense and acts as a shell that 
covers the entire long bone to provide biomechanical support and fulfill homeostatic 
demands " . Alternatively, cancellous bone, which is also known as trabecular bone, is 
less dense and has a network structure with a spongy texture. Cancellous bone is present 
in the inner region of bone to provide biomechanical support and protective properties. 
Bone Formation 
The formation of bone occurs by either intramembranous or endochondral 
ossification. Intramembranous ossification takes place in flat bones such as the shell of 
cortical bones, cranial and mandible6, and occurs without going through a cartilage 
intermediate7. Endochondral ossification, on the other hand, takes place in long bones 
and occurs through a cartilage intermediate. 
The two stages of bone development are matrix formation and mineralization. In 
intramembranous ossification, immature progenitor cells progress into preosteoblasts and 
then into osteoblasts7. Osteoblasts, which are 15-30 um cuboidal-shaped cells, synthesize 
and secrete collagen to form unmineralized bone matrix (i.e., osteoids) and arrange side-
by-side to form a sheet that covers the bone forming surface6. After depositing osteoids, 
osteoblasts will regulate the deposition of calcium phosphate in the osteoids which results 
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in mineralization. The osteoblasts that are surrounded in the mineralized bone matrix then 
turn into osteocytes which have a stellate morphology. The osteocytes, which make up to 
95% of total bone cells, play a part in bone matrix mineralization by regulating the 
movement of mineral ions from the extracellular fluid to form hydroxyapatite crystals . 
Bone is a very unique tissue because it is the only tissue in the body that continuously 
remodels itselr through cycles of bone formation by osteoblasts and bone resorption by 
osteoclasts ' . Osteoclasts, which are 20-100 um multinucleated cells, adhere to 
mineralized matrix and form a small chamber that is sealed from the extracellular fluid to 
maintain a suitable microenvironment for bone resorption. Once they complete their 
resorptive function, osteoclasts move into marrow spaces close by and undergo 
apoptosis . 
In endonchondral ossification, cartilage, which is an avascular tissue, is converted 
into bone, which is one of the most highly vascularized tissues in the body1 . The 
chondrocytes in the cartilage become hypertrophic and begin secreting alkaline 
phosphatase which is essential for matrix calcification. The calcified hypertrophic 
cartilage is then penetrated by capillary vascular buds. Hypertrophic chondrocytes 
undergo apoptosis and the cartilage matrix is degraded, resulting in a vascularized cavity. 
Osteoblasts, formed from osteoprogenitor cells that enter the cavity, deposit osteoids in 
the area which are then replaced by trabecular bone. 
Repairing Bone Defects 
Effective approaches are much needed to repair bone defects caused by trauma, 
cancer, congenital abnormalities or age-related degeneration11"14. The repair of these 
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defects is still a challenge for orthopedic and reconstructive surgeons. The healing of a 
defect involves a very complex cascade of events. When an injury occurs as in a bone 
defect, the body responds by going through hemostasis (i.e., process that causes bleeding 
to stop), clearing cellular debris from the defect site and forming fibrous vascularized 
connective tissue15'1 . The formation of a scar or regeneration of the tissue then takes 
place at the defect site. The cells at the defect site are mostly fibroblasts and 
inflammatory cells such as macrophages, lymphocytes, plasma cells and neutrophils, 
depending on the stage of the fibrous connective tissue development and whether 
infection is present . Cytokines and growth factors in the local environment control the 
migration, proliferation and differentiation of the cells at the defect. Vascularization at 
the defect site is important for the recruitment of osteoprogenitor cells . For bone, 
defects that have large bone loss or insufficient vascularity will not be conducive to 
regenerating by themselves . Thus, aid is needed in healing such bone defects and 
different strategies are currently being investigated to guide the complex bone healing 
process in these defects. 
Current Methods for Bone Repair 
Current approaches for repairing bone defects include artificial prostheses and 
bone grafts20. Treatment of bone defects using artificial prostheses made from materials 
such as metal alloys and ceramics has been widely tested, however, there are several 
disadvantages associated with them. Before surgically placing these prostheses, a large 
amount of bone near the defect site has to be removed. Furthermore, non-
7 
biocompatibility of the artificial materials21 and the high cost of these prostheses are also 
limiting factors associated with this bone treatment method20. 
Among the strategies that are currently being applied to repair bone defects, bone 
grafting is the method that is most prominently used22. Bone grafts are usually harvested 
from the iliac crest of the patient or a donor23. In autogenous bone grafting, grafts from 
the same patient are used, whereas in allogenous bone grafting, grafts from donors are 
used24. The success of these grafts lies in the fact that they are comprised of components 
that are necessary for enhancing bone formation such as bone and progenitors cells and 
7S 
appropriate growth factors . Due to problems faced when using bone grafts such as pain 
at the donor site, the need for two surgeries, availability of appropriate grafts with the 
right shape and volume as well as the risk of infection, other methods are being 
77 
investigated to replace this current preferred method of healing bone defects . 
Bone Tissue Engineering 
Researchers have been focusing on the application of tissue engineering as an 
alternative approach to the current methods for treating bone defects. Tissue engineering, 
as defined by Boyan et al., is the "design, construction, modification, growth and 
maintenance of living tissue and organs from native or synthetic materials using scientific 
engineering principles with resources from molecular developmental biology, cell 
biology and biomaterial sciences"26. The ultimate goal of tissue engineering is to use the 
body's own capacity instead of grafts or artificial prostheses, to guide the wound healing 
process toward tissue regeneration. 
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Bone tissue engineering has been investigated to treat isolated bone defects which 
include fractures and non-unions27 as well as bone diseases such as osteoporosis and 
osteogenesis imperfecta ' . The ideal bone tissue engineering material should be 
osteoconductive as well as osteoinductive. An osteoconductive material is inert and 
allows the ingrowth of host tissue20. Alternatively, an osteoinductive material has the 
ability to induce osteogenic differentiation of mesenchymal stem cells (MSCs)30. The 
tissue engineering paradigm for bone and other tissues includes three general factors 
which are scaffolds, cells and bioactive molecules such as growth factors or genes 
encoding the growth factors. These three factors can be used singly or in combination to 
develop a tissue engineering system for a particular defect. 
Delivery of Growth Factors to Promote Bone Formation 
Tissue engineering systems, which deliver bioactive factors such as growth 
factors, can be a promising bone treatment method to replace the existing strategies for 
repairing bone defects. Growth factors are cell secreted proteins that can modulate cell 
activity by stimulating or inhibiting cellular proliferation, differentiation, migration, 
adhesion, apoptosis or gene expression31. Growth factors can interact with cell surface 
receptors of either the cell that produced and secreted the protein itself or a neighboring 
cell . It has been shown in the literature that clinical fractures treated with growth factors 
had no significant difference after a 9-month healing period compared to those treated 
with autogenous cancellous bone grafts33. However, patients treated with the grafts had 
increased hospitalization, surgery time and blood loss from the donor site during surgery. 
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The delivery of growth factors to the local site can aid in fracture healing while avoiding 
the complications associated with bone grafts 
Growth factors are typically delivered as recombinant proteins produced using 
microbes such as Escherichia coli (E. coli) or a mammalian cell line such as Chinese 
hamster ovary (CHO) cells35. The gene that encodes the growth factor of interest is 
transfected into the cells where the gene is then transcribed and translated to produce the 
recombinant protein of interest. Fibroblast growth factors (FGFs), platelet-derived growth 
factors (PDGFs), insulin-like growth factors (IGFs), bone morphogenetic growth factors 
o 
(BMPs) and transforming growth factors (TGFs) are examples of growth factors that are 
capable of promoting the differentiation of MSCs into different lineages. 
Bone Morphogenetic Protein 
BMPs are members of the TGF-P superfamily and are osteoinductive factors that 
have been identified to facilitate skeletal development and the formation of bone8'3 . 
BMPs can stimulate angiogenesis, which is the formation of new capillary vessels from 
-1*7 TO Af\ 
existing vessels , as well as promote proliferation of MSCs " . BMPs can also behave 
as chemotactic agents by initiating the recruitment of osteoprogenitors and MSCs toward 
the defect site and stimulate the differentiation of these cells into an osteochondroblastic 
lineage41. Fifteen BMPs have been identified to date and they have varying capabilities 
of inducing osteogenesis in different types of cells42. Among them, BMP-1 has been 
shown to be incapable of inducing bone formation43 and BMP-2, 4 and 7 have been 
established as successful osteoinductive factors42. A sufficient amount and duration of 
BMP expression at the defect site is needed to induce bone formation25'44. Many 
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researchers in bone tissue engineering have investigated the delivery of these 
osteoinductive factors in the form of the protein itself or the gene that encodes for the 
protein of interest. 
Gene Therapy 
The original objective of gene therapy is to deliver a gene to replace a defective 
gene19. However, the field of gene therapy has evolved to encompass introducing a new 
gene that encodes a specific therapeutic protein to a defect site in order to alter or control 
the path of cellular action45. Researchers have successfully identified growth factors that 
can enhance the formation of particular tissues, which has led to the production of these 
proteins for therapeutic purposes. A lot of research has been focused on delivering these 
growth factors for bone tissue engineering. However, shortcomings associated with 
delivering growth factors in the protein form have led to the use of gene therapy as an 
alternative approach to deliver the gene that encodes the growth factor of interest. 
Compared to the delivery of proteins, gene therapy allows for a longer bioavailability of 
the growth factor as DNA has a longer half-life compared to proteins46. Furthermore, 
manufacturing growth factors is expensive and more difficult compared to manufacturing 
the genes that encode the growth factors. By using gene therapy, the growth factors are 
synthesized in vivo, and as a result, the growth factors can be delivered in a more 
biologically active form34 with more precise post-translational modification and tertiary 
structure formation47'48. Using gene therapy instead of delivering the BMP in the protein 
form for bone tissue engineering has been proven to result in higher total bone volume , 
11 
more efficient and organized bone formation5 while requiring a smaller dose to enhance 
bone formation51. 
Barriers of Gene Therapy 
In gene therapy system for bone tissue engineering, a gene is usually delivered to 
the cells at a defect site either by itself (i.e., naked DNA) or using a viral or non-viral 
gene delivery vector. DNA that is delivered for gene therapy has to face many obstacles 
before it can be transcribed into a messenger RNA (mRNA) and translated into the 
protein of interest in the cell nucleus. Some of these barriers can be overcome by 
delivering the DNA using a gene delivery vector 
When designing a gene delivery system, several gene delivery barriers have to be 
taken into consideration to ensure that the DNA is delivered successfully. The first barrier 
or rate limiting step is to deliver the DNA to the desired area of interest without it 
interacting with the reticular endothelial system . This barrier can be overcome by 
delivering the DNA directly to the site of interest via injection or using an implanted 
carrier, rather than finding a method to circumvent the clearance of the DNA as it flows 
systemically to the site of interest. 
Once at or near the site of interest, the DNA has to face the obstacle of entering 
cells as the cell membrane limits the transport of undesired molecules like DNA. DNA 
can be interacted with a gene delivery vector to form a complex that can be delivered 
using the same method that is used by cells to transport waste and nutrients to and from 
the environment. These vector/DNA complexes are transported into the cells using 
clathrin-coated pits which are internalized from the plasma membrane through a process 
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called endocytosis . To ensure successful delivery through endocytosis, the complexes 
have to be around 100 nm or less in diameter to be able to fit in the clathrin-coated pits54. 
Although complexes larger than 100 nm are unable to get endocytosed by cells, they have 
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been shown to transfect cells successfully ' through an unknown mechanism ' . 
Once successfully in the cell, the endocytosed DNA has to then face the obstacle 
of escaping from the endosomal compartment to avoid getting degraded in the lysosome . 
pH sensitive gene delivery vectors that can buffer between pH 5.0 to 7.4 can help 
facilitate the release of DNA from the endosome through the proton sponge effect . At 
low pH, as vectors buffer the pH by accepting hydrogen ions, the endosome will try to 
maintain the osmotic and charge balances, which will results in an influx of water and 
chloride counterions into the endosome. This causes the endosome to burst and results in 
the release of the DNA into the cytoplasm. 
When the DNA successfully escapes from the endosome, it has to face the 
obstacle of translocation into the cell nucleus where its genetic code can then be read to 
produce the protein of interest52. The nuclear pores only allow particles of about 70 kDa 
(DNA with -117 base pairs) to enter through free diffusion60. To deliver DNA larger than 
70 kDa through the nuclear pores, a nuclear localization sequence (NLS) can be 
incorporated into the DNA sequence which functions to direct the complex into the 
nucleus53. However, instead of entering through the nuclear pores, DNA can be 
transferred into the nucleus during mitosis where the nuclear membrane is broken down . 
Once in the nucleus, the DNA has to face the barrier of incorporating itself into 
the cell's DNA in order for the gene to be actually expressed by the cell. The complete 
DNA sequence that encodes all the proteins in an organism is known as the genomic 
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DNA . This set of DNA is the same in each cell of the individual organism and it is 
replicated at every somatic cell division. DNA sequences are transcribed into mRNA 
which are then translated into specific proteins. Since mRNA are unstable, there is 
usually only transient production of protein from a specific mRNA . In gene therapy, the 
DNA that encodes a particular growth factor to be delivered is considered exogenous 
DNA which does not get replicated in each somatic cell division. This DNA sequence 
consists of a promoter region which determines whether the gene will be expressed along 
with coding region for the protein of interest . The promoter is regulated by the local 
environment in the host cell and the gene will only be expressed if it receives the required 
stimuli in the cell. If the gene does not receive the correct stimuli, the promoter will 
remain inactive , thus, the protein of interest will not be produced. Ideally for gene 
therapy, the DNA sequence should incorporate the promoter that is generally activated in 
the cell that will internalize the DNA to ensure that the desired protein is expressed when 
the exogenous gene is delivered into that cell. However, such promoters of cellular 
proteins are often large in size and not well characterized64. Therefore, promoters that 
resemble the promoters for viruses such as cytomegalovirus (CMV) or retrovirus are used 
instead as cells are known to respond to these promoters . These viral promoters are 
often inactivated by methylation because they are recognized as foreign by the host cell, 
thus, eventually resulting in a decrease in gene expression after some time65. Therefore, a 
continuous delivery of the exogenous DNA is needed to ensure that the protein of interest 
is continuously produced. 
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Non-Viral Gene Delivery Vectors 
Viral vectors such as adenovirus, adeno-associated virus, lentivirus and retrovirus 
have been shown to be very efficient at delivering DNA. However, due to the 
disadvantages such as immune and toxic responses, production complexity and cost of 
these vectors56'67, non-viral vectors are increasingly being investigated as an alternative to 
replace viral vectors. Unlike viral carriers, DNA delivered using a non-viral vector is 
inserted into a plasmid which does not have a limitation on the size of the gene it can 
carry. The idea behind designing a successful non-viral gene delivery vector is to develop 
/TO 
a material that will mimic the viral infection process which has been shown to be very 
efficient at delivering a gene. The non-viral vector must be able to condense the DNA 
and protect it from degradation by nucleases. It also must form complexes that can 
transfect cells successfully and assist in endosomal escape. 
One type of non-viral vectors currently being investigated is cationic lipids. These 
lipids are usually composed of a hydrophilic lipid anchor that is made out of a cholesterol 
or fatty acid group, and a cationic head group19. These two groups are connected by an 
intermediate group which is able to control the chemical stability and biodegradability of 
the cationic lipids, and can be used to attach targeting, cell uptake and intracellular 
trafficking moieties69. The hydrophilic portion of the cationic lipids plays a role in 
determining the flexibility and kinetics of the lipid exchange in the bilayer . Tightly 
condensed complexes known as lipoplexes are formed when DNA and cationic lipids 
interact with each other. This interaction occurs as a result of the increase in entropy that 
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is derived when water molecules and counter ions are released from the surfaces of the 
DNA and the lipids71. 
Beside lipids, polymeric materials have also been investigated for application as 
non-viral gene delivery vectors. Neutral charged polymers such as poly(vinyl pyrrolidone) 
(PVP) and poly(vinyl alcohol) (PVA) have been used to deliver DNA72. These polymers 
are amphiphilic molecules that have hydrophobic backbones and hydrophilic side chains 
which can participate in hydrogen bonding. These polymers can interact with and 
stabilize DNA by hydrogen bonding as well as protect the DNA from nuclease 
degradation73. 
Positively charged polymers can also serve as gene delivery vehicles by 
electrostatically interacting with negatively charged DNA. Amines are basic groups and 
the lone pair electrons on the nitrogen of the amines can gain a proton which results in a 
positive charge. DNA has a negatively charged backbone made out of phosphodiseter 
groups that is highly extended due to the repulsion of the negative forces. This results in 
the large size of DNA which causes a problem for cellular uptake74. Polycationic 
polymers can be used to address this problem by acting in a similar way as nucleosomal 
proteins, such as histones, to condense and compact DNA59. Through electrostatic 
interactions with the polycationic polymers, the negative charges on the DNA are 
shielded, thus, reducing the repulsion between the negative charges on the DNA 
backbone. This capability of polycationic polymers make them more advantageous as 
non-viral gene delivery vectors compared to uncharged polymers. Furthermore, 
polymer/DNA polyplexes with a net positive charge, are able to enhance cell adhesion by 
interacting with the negatively charged phospholipids and sulfate groups of proteoglycans 
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on the cells59'75. Delivering DNA with a polycationic polymer instead of by itself (i.e., as 
naked DNA) significantly reduced the required dose of DNA to induce a biological 
response from the milligram range7 to the microgram range 7. 
Various types of polycationic polymers have been synthesized and evaluated as 
vectors for non-viral gene delivery. These polymers can be in the form of linear, 
branched or dendrimeric molecules, and have different advantages and disadvantages 
associated with them. Polyethylenimine (PEI)78 is a polycationic polymers that have been 
highly investigated. Although PEI is known to be an effective non-viral gene delivery 
vector, its toxicity and non-degradability present a problem with repeated dosage and 
long-term usage due to its accumulation in the endosomal compartment or cell 
nucleus7 ' . Thus, biodegradable polymers with high transfection efficiencies and low 
cytotoxicity are much needed to replace current non-biodegradable polycationic 
polymers such as PEI. 
Biodegradable Polycationic Polymers 
Biodegradability of polycationic polymers is important to facilitate the release of 
an encapsulated DNA once it is delivered into a cell. Furthermore, biodegradation of the 
polymers is key in the excretion of the polymers and their degradation products to avoid 
accumulation in the endosomal compartment or cell nucleus . In designing a 
biodegradable polycationic polymer for gene delivery, the optimal degradation rate of the 
side chains or part of the main chain of the polymers is an important criterion to consider. 
The polymer should not degrade too quickly to avoid the disassembling of the DNA from 
the polyplex too early during the delivery process, making the DNA susceptible to 
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enzymatic degradation and reducing the DNA transfection efficiency. Alternatively, the 
polymer should degrade fast enough for the DNA to disassemble from the polyplex once 
the polyplex has reached the cytoplasm or nucleus to allow for DNA expression81'82. By 
degrading into lower molecular weight fragments, the density of positive charges in the 
polymer is decreased. This results in a decrease in the cytotoxicity of the polymer as 
interaction with cellular compartments is reduced83'84. 
Biodegradable polymers consist of degradable functional groups such as esters 
91
, disulfides92 and urethanes93"95. These polymers can be synthesized from different 
monomers where the degradable unit is in one of the monomers or is formed during the 
reaction. Biodegradable polymers can also be synthesized by reacting low molecular 
weight molecules of existing non-biodegradable polymers such as PEI, with a degradable 
linker consisting of esters or disulfide bonds. High molecular weight PEI, which is 
currently one of the most effective polymers for gene delivery, forms polyplexes with 
high transfection efficiency but exhibits high toxicity to the cells. Alternatively, low 
molecular weight PEI exhibits lower toxicity but forms polyplexes which are not efficient 
at transfection 8'97. By linking low molecular weight PEI with a degradable linker, a 
highly branched polymer with high transfection efficiency and improved toxicity can be 
obtained. 
DNA can also be delivered with biodegradable micro- or nanoparticles which can 
be synthesized from biodegradable natural as well as synthetic materials. Particles 
go 
synthesized from PLGA are the most studied gene delivery particles in the literature . 
Although PLGA is a commercially available material that is FDA approved and widely 
used for medical applications and drug delivery, the material has several drawbacks for 
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DNA delivery. The large size and hydrophilic nature of DNA make it difficult to be 
encapsulated in the hydrophobic PLGA material. Furthermore, hydrolysis of PLGA 
results in the release of acidic byproducts that can lower the pH in the particles which 
maybe detrimental to the encapsulated DNA99'100. 
A class of biodegradable polycationic polymers that has been highly investigated 
recently is poly(amino ester)s. One method to synthesize this class of polymers is by 
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Michael addition polymerization of diacrylate ' ' or triacrylate ' ' monomers with 
amine monomers. This synthesis as well as the resulting polymers formed from this 
synthesis has many advantages associated with them. The synthesis of these polymers is 
performed in a one-pot reaction that does not require a catalyst, which would need to be 
removed through a purification process. The resulting polymers are degradable by ester 
hydrolysis which results from the ester groups in the acrylate monomers. Unlike 
polycondensation or amidation reactions, Michael addition polymerization preserves the 
basicity of the amine groups, even when they participate in the reaction. Thus, the amines 
that participate in the reaction can still be beneficial to the gene delivery process. 
Lynn et al. have synthesized such polycationic polymers from diacrylate and 
amine monomers88,89. In one of their studies, they synthesized polymers from 1,4-
butanediol diacrylate (BDA) and three different amine monomers which were N,N'-
dimethyl ethyl enediamine, piperazine and 4,4'-trimethylenedipiperidine. They 
demonstrated that these polymers were successfully degradable hydrolytically in acidic 
and alkaline media89. In another study, Lynn et al. synthesized a library containing a total 
of 140 structurally unique polymers88. Seventy of these polymers were sufficiently water-
soluble and were able to bind DNA. They found that polymers containing l-(3-
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aminopropyl)imidazole (API) were similar in structure to other histidine containing 
polymers and the imidazole groups, which have buffering capacity, allowed these 
polymers to mediate endosomal escape. The linear polycationic polymer synthesized with 
BDA and API successfully resulted in a transfection efficiency that was 4-8 times higher 
than PEL 
In contrast to Lynn et al., some groups have synthesized biodegradable 
poly(amine ester)s by reacting triacrylate monomers, instead of diacrylate monomers, 
with amine monomers via Michael addition polymerization resulting in branched 
polymers instead of linear polymers. Linear polycationic polymers usually have a much 
faster degradation rate compared to branched polymers. This causes them to release the 
encapsulated DNA too early during the delivery process which may be detrimental to the 
DNA101. Compared to linear polymers, branched polymers have degradative sites that are 
more hidden inside the numerous branches of the polymer, thus, the degradation rates of 
these polymers can be prolonged. Furthermore, amines in branched polymers are more 
sterically hindered compared to those in linear polymers. As a result, the amines in 
branched polymers are more difficult to protonate which increases their buffering 
capacity and ability to assist in endosomal escape. 
Wu et al. are among the groups that have successfully synthesized these 
poly(amine ester)s with a triacrylate monomer. Wu et al. synthesized a hyperbranched 
polymer using trimethylolpropane triacrylate (TMPTA) and l-(2-aminoethyl)piperazine 
(AEPZ) by Michael addition polymerization87. The polymer contained primary, 
secondary and tertiary amines similar to those in the well established polymer PEL 
Although PEI has been shown to be very efficient at transfecting cells, its non-
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degradability can be a problem. Wu et al. demonstrated that they were able to synthesize 
a polymer with amine constitutions similar to PEI that formed polyplexes with higher 
transfection efficiency and was degradable and non-toxic compared to PEI. Kim et al. 
have also successfully synthesized hyperbranched poly(amine ester)s with a triacrylate 
monomer91. To synthesize their polymers, they used pentaerythritol triacrylate (PET) 
which is a triacrylate monomer that has an additional hydroxyl functional group 
compared to TMPTA, to allow further modification of the synthesized polymer and 
enhance water solubility. Kim et al. reacted PET with amine monomer N,N-
dimethylethylenediamine (DED), and modified the hydroxyl group on PET by reacting it 
with aminohexanoic acid or lysine that contains amines to increase the amount of positive 
charges in the polymers. Kim et al. showed that the polymer that was modified with 
aminohexanoic acid goes through a stepwise degradation process as a result of the 
differences in susceptibility of the ester bonds to hydrolysis. 
Delivery of Polymer/DNA Polyplexes with a Carrier 
Unlike the delivery of DNA in vitro, there are more issues that have to be taken 
into consideration when designing a vector that will be successful in transfecting cells in 
vivo. Delivery of DNA in vivo can be performed systemically through the blood 
circulation or locally to a particular site of interest. Systemic delivery can be 
advantageous for the delivery of DNA to sites that are inaccessible or difficult to access 
for local applications . This delivery method is more suitable for the treatment of 
patients with diseases where a particular gene has to be delivered to every host cell such 
as for osteogenesis imperfecta or Gaucher's disease. For osteoporosis where multiple 
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sites have a deficiency in mineralization, systemic delivery may also be a more suitable 
treatment compared to local delivery . Although more suitable for some applications, 
systemic delivery of the DNA is much more challenging than local delivery as the DNA 
will have to traverse harsh environments to get to the specific target site. Thus, local 
delivery of the gene at or near the defect site using a bone tissue engineering system may 
be more beneficial for some applications. By using this method, there will be a higher 
chance that the DNA will be delivered to the targeted area successfully. Thus, a lower 
dose of DNA will be required to illicit a therapeutic response as compared to delivering 
the DNA systemically. 
In developing a successful gene therapy system for bone tissue engineering, the 
gene delivery vector is not the only important factor to take into consideration. The 
carrier (i.e., scaffold or composite scaffold) that is used to deliver the vector/DNA 
complexes also plays a critical role in the gene therapy strategy104. In a gene therapy 
system, the gene delivery vector is important for the complexation and condensation of 
the DNA. The vector also protects the DNA from degradation, facilitates the interaction 
of the DNA with the negatively charged cells and assists in the endosomal escape of the 
DNA once in the cells. Alternatively, the carrier plays an important role in delivering the 
vector/DNA complexes to a specific site, controls the release kinetics of the complexes 
and protects the vector from degradation before the complexes are delivered into the cells. 
Furthermore, an ideal carrier for bone tissue engineering should have strong mechanical 
properties that are similar to bone, high porosity and interconnectivity, good 
biocompatibility and should be biodegradable. The carrier should also provide a three-
dimensional environment for the proliferation and differentiation of osteoprogenitor 
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cells . Certain properties of the carrier such as the degradation rate, porosity and 
mechanical strength can be tailored to fit the defect site of interest. 
The delivery of DNA using this two level (i.e., vector and carrier) delivery system 
approach have been investigated by many groups46'77'105'106. A delivery system with just 
one of these components will not be as efficient as when both components are 
incorporated. Without the vector, the DNA will be delivered as uncondensed DNA which 
is not protected from degradation. Delivery of naked DNA has been shown by many 
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groups, including ours, to be less efficient at transfecting cells ' . Alternatively, 
without the carrier, the entire dose of vector/DNA complexes will be delivered as a bolus 
delivery at the site of interest. This may not result in a therapeutic effect when a sustained 
release of the growth factor such as BMP-2 is required to heal the defect site . 
Appropriate concentrations of growth factors delivered for sufficient time is important to 
avoid retarded or no improvement in the rate of bone healing . For gene delivery, the 
DNA encoding the growth factor will be delivered instead of the protein itself. For 
successful bone formation, the DNA should be delivered in a controlled manner so that 
the cells will be able to produce a sufficient concentration of the protein in a sustained 
manner. 
Several research groups have used PEI as the vector to deliver DNA in a 
biodegradable carrier system since PEI is a well established vector that has been shown to 
be a very efficient non-viral gene delivery vehicle. Lim et al. delivered PEI/DNA 
polyplexes by electrostatically encapsulating them into water-soluble chitin and alginate 
fibers which have a net positive and net negative charge, respectively . Polyplexes of 
PEI with DNA encoding basic FGF that were released from these scaffolds were able to 
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retain their bioactivity and transfect cells seeded on the scaffolds. The escape of 
polyplexes from the fiber scaffolds depended on the electrostatic interaction of the 
charges on the scaffolds with ions in the culture medium and the degradation rate of the 
scaffolds. Lim et al. found that human dermal fibroblasts transfected with polyplexes 
released from these 3D scaffolds had prolonged secretion of basic FGF for 2 weeks with 
levels that were significantly higher than the baseline. However, 2D controls with a bolus 
delivery of PEI/DNA polyplexes showed expression for only 3 days. The highest 
concentration of secreted basic FGF in the 2D controls was notably lower than for the 3D 
scaffolds. The results from this study showed that by incorporating a 3D scaffold carrier, 
continuous delivery of the PEI/DNA polyplexes could be achieved and the polyplexes 
could be delivered directly into the cellular microenvironment in the scaffold which 
enhanced the bioavailability of the DNA. 
Huang et al. also delivered PEI/DNA polyplexes in a sustained and localized 
approach using a biodegradable carrier. They incorporated these polyplexes in a PLGA 
scaffold and delivered the composite scaffold in a critical-size rat cranial defect77. Naked 
DNA encoding BMP-4 delivered in the PLGA scaffolds and blank PLGA scaffolds 
produced bone formation mainly on the edges of the defect. DNA that was condensed 
with PEI and then encapsulated in the PLGA scaffolds, however, showed bone formation 
at the edges as well as within the defect site. Furthermore, the total bone formation was at 
least 4.5-fold more than the other two types of scaffolds. Delivery of condensed DNA 
with a vector led to more complete mineralized tissue formation as shown by an increase 
in osteoid and mineralized tissue density in the defect site. These results demonstrated the 
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advantage of using a non-viral polycationic vector to deliver DNA from a scaffold carrier 
compared to delivering DNA in the naked, uncondensed form. 
Conclusions 
Due to the limitations and problems associated with current bone repair strategies, 
a lot of research has been focused on using tissue engineering as an alternative approach. 
Bone tissue engineering systems incorporating plasmid DNA (pDNA) encoding BMP-2 
complexed with a polycationic polymer is a promising application for repairing bone. 
Although current polycationic polymers such as PEI are known to be effective non-viral 
gene delivery vectors, their toxicity and non-degradability present a problem with 
repeated dosage and long-term usage due to their accumulation in the endosomal 
compartment or cell nucleus ' . Thus, biodegradable polycationic polymers are being 
designed and synthesized to replace these non-degradable vectors. In this work, 
triacrylate/amine polycationic polymers (TAPPs) with different hydrophilic spacer 
lengths and amine basicities were synthesized by Michael addition polymerization. We 
hypothesized that by altering the hydrophilic spacer lengths and amine basicities in the 
TAPPs, the polymer and polymer/pDNA polyplex characteristics which are important for 
gene delivery can be tailored. To evaluate these TAPPs in a bone tissue engineering 
system, TAPPs/pDNA polyplexes were incorporated into a composite containing acidic 
gelatin microparticles (GMPs) and a porous poly(propylene fumarate) (PPF) scaffold. We 
hypothesized that the degradation rates of the TAPPs and GMPs can affect the release 
kinetics of the pDNA and that composite scaffolds containing TAPP/pDNA polyplexes 
will result in enhanced bone formation compared to those containing naked pDNA. 
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CHAPTER III 
SYNTHESIS AND CHARACTERIZATION OF BIODEGRADABLE BRANCHED POLYCATIONIC 
POLYMERS WITH VARYING HYDROPHILIC SPACERS FOR NON-VIRAL GENE DELIVERY f 
Abstract 
Biodegradable branched polycationic polymers with varying hydrophilic spacer 
lengths were synthesized from different triacrylate monomers and the amine monomer 1 -
(2-aminoethyl)piperazine by Michael addition polymerization. The hydrophilic spacers 
were varied by the number of ethyleneoxy groups in the triacrylate monomer (E/M) that 
ranged from 0 to 14. The polymer degradation depended on the spacer length and pH; the 
amount of ester degraded as determined by 'H-NMR after 14 days was 43.4 ±2.1% (pH 
5.0) and 89.7 ± 1.3% (pH 7.4) for the polymer with 0 E/M compared to 55.7 ± 2.6% (pH 
5.0) and 98.5 ± 1.6% (pH 7.4) for the polymer with 14 E/M. Cell viability of rat 
fibroblasts after exposure to polymer solutions of concentrations up to 1000 |j,g/mL 
remained high (above 66.9 ± 12.1% compared to below 7.6 ± 1.1% for polyethylenimine 
at a concentration of 50 [xg/mL or higher) and increased with the spacer length. The 
polyplexes made with all the synthesized polymers showed higher transfection efficiency 
(4.5 ± 1.7%o to 9.4 ± 2.0%), dependent on the polymer/pDNA weight ratio) with an 
enhanced green fluorescent protein reporter gene compared to naked pDNA (0.8 ± 0.4%) 
as quantified by flow cytometry. This study demonstrates that hydrophilic spacers can be 
This chapter has been published as follows: S.A. Chew, M.C Hacker, A. Saraf, R.M. Raphael, F.K. 
Kasper, and A.G. Mikos, Biodegradable Branched Polycationic Polymers with Varying Hydrophilic 
Spacers for Non-Viral Gene Delivery, Biomacromolecules, 10, 2436-2445 (2009). 
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incorporated into polycationic polymers to reduce their cytotoxicity and enhance their 
degradability for non-viral gene delivery. 
Introduction 
Gene therapy can be used to alter or control the path of cellular action19 by 
replacing a defective gene or introducing a new gene that encodes for a specific 
therapeutic protein45. Viral vectors have been shown to be very efficient at delivering 
DNA. However, due to safety concerns such as immune and toxic response, production 
complexity and cost of these vectors66'67, non-viral vectors such as polycationic polymers 
are increasingly being investigated as an alternative method for gene delivery. Such 
polymers, which frequently contain positively charged protonated amine groups, are able 
to interact electrostatically with the negative charges of the phosphate groups on the 
DNA backbone leading to DNA condensation and protection against DNA degradation. 
Furthermore, positively charged polymer/DNA polyplexes may better adhere to cells by 
interacting with the negatively charged phospholipids and sulfate groups of the 
proteoglycans on the cells59'109, which ultimately helps with the internalization of the 
polyplexes by endocytosis. The pH in such newly formed endosomes gradually decreases 
and reaches values of 4.5 when the endosome becomes a lysosome ' . Any amine 
groups that buffer between pH 7.4 to 5.0 can assist in the escape of the DNA from the 
endosome and prevent DNA degradation by nucleases in the lysosome through the proton 
sponge effect . 
Biodegradable polymers with high transfection efficiencies are much needed as 
more cytocompatible alternatives to current non-biodegradable polycationic polymers, 
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such as polyethylenimine (PEI)78 and poly(dimethylaminoethylmethacrylate) 
(PDMAEM)110. Although PEI and PDMAEM are known to be effective non-viral vectors, 
their toxicity and non-degradability presents a problem with repeated dosage and long-
term usage due to their accumulation in the endosomal compartment or cell nucleus79'80. 
Biodegradability of polycationic polymers is important to facilitate the release of 
encapsulated DNA once in the cell and to excrete the polymers and their degradation 
products to avoid accumulation in the endosomal compartment or cell nucleus81. An 
optimal degradation rate of the side chains or part of the main chain of the polymers is a 
key design criterion of polymers for non-viral gene delivery. If the polymer degrades too 
quickly, the DNA will disassemble from the polyplex too early during the delivery 
process. As a result, the degraded polymer will not complex with and condense the DNA, 
thus making the DNA susceptible to enzymatic degradation. On the other hand, the 
polymer should degrade fast enough for the DNA to disassemble from the polyplex once 
the polyplexes have reached the cytoplasm or nucleus to allow for plasmid expression ' . 
Degradation of the polymer into lower molecular weight fragments is further desirable as 
it decreases the cytotoxicity of the polymer by decreasing the density of positive charges, 
thus, reducing any interaction with cellular compartments83'111. 
Biodegradable polymers synthesized by Michael addition polymerization of 
acrylate and amine monomers have been previously investigated as non-viral gene 
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delivery vectors " . These polymers can be synthesized from either diacrylate ' ' ' or 
triacrylate87'90'91 monomers, to produce either linear or branched polymers, depending on 
the type of amine monomer used in the synthesis. The acrylate monomers contain ester 
groups, which contribute to the hydrolytic biodegradability of the polymers. The 
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/'polymers are synthesized in a one-pot reaction that does not require a catalyst, which 
would have to be isolated during the purification process. In contrast to polycondensation 
or amidation reactions, addition polymerization preserves basicity of the amine groups, 
even when they participate in the reaction. 
In this work, a series of polymers were synthesized by chemically conjugating 
different triacrylate monomers with a single amine monomer, 1 -(2-aminoethyl)piperazine 
(AEPZ) to test the hypothesis that hydrophilic spacers can be incorporated into 
polycationic polymers to produce gene delivery vectors with reduced cytotoxicity and 
enhanced degradability. The hydrophilic spacers in these polymers consist of ethyleneoxy 
groups, equivalent to those found in poly(ethylene glycol) (PEG), which is often 
incorporated into polymers to increase the hydrophilicity and chain flexibility of the 
polymers as well as to decrease the cytotoxicity of polymeric non-viral vectors ' .To 
test this hypothesis, we investigated the effects of the hydrophilic spacer lengths 
(different triacrylate monomers) on the molecular weight, amine equivalents protonating 
at different pH values, degradability and cytotoxicity of the synthesized polymers as well 
as the diameter, zeta potential and transfection efficiency of the polyplexes formed by 
these polymers with plasmid DNA (pDNA), all of which are relevant parameters in 
designing a gene delivery vector. 
Materials and Methods 
Materials 
Trimethylolpropane triacrylate (TMPTA), 3 types of trimethylolpropane 
ethoxylate triacrylates (TMPETA) that differ in the average number of ethyleneoxy 
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groups per molecule (TMPETA with 3 ethyleneoxy groups per monomer (3E/M), 
TMPETA with 7 ethyleneoxy groups per monomer (7E/M) and TMPETA with 14 
ethyl eneoxy groups per monomer (14E/M)), AEPZ, branched PEI (typical weight 
average molecular weight, Mw ~ 25 kDa, polydispersity (PDI) of 2.5), chloroform (ACS 
grade), sterile-filtered dimethyl sulfoxide (DMSO), methyl tetrazolium (MTT) powder, 
phenol red free Dulbecco's modified Eagle medium (DMEM), ethidium bromide and 
Tris-Acetate-EDTA (TAE) were purchased from Sigma-Aldrich (St. Louis, MO). 
Deuterium oxide (D2O) was obtained from Cambridge Isotope Laboratories, Inc. 
(Andover, MA). Acetone (ACS grade), isopropanol (ACS grade) and Fisher Certified 
Buffer pH 5.0 and 7.4 were purchased from Fisher Scientific (Pittsburgh, PA). Fischer rat 
fibroblast 3T3-like cell line (CRL 1764) was obtained from American Type Culture 
Collection (Manassas, VA). DMEM, phosphate-buffered saline (PBS), penicillin, 
streptomycin and amphotericin B were purchased from Gibco Life (Grand Island, NY). 
Fetal bovine serum (FBS) was obtained from Gemini Bio-Products (Calabasas, CA). 
Trypsin-ethylenediaminetetraacetic acid (EDTA) (0.25% trypsin/0.02% EDTA) was 
obtained from Invitrogen (Carlsbad, CA). Poly(ethylene glycol) (PEG) standards with 
number average molecular weights (Mn) ranging from 102 to 82,500 Da were obtained 
from Waters (Milford, PA). Plasmid DNA (pDNA) with a cytomegalovirus (CMV) 
promoter and enhanced green fluorescent protein (eGFP) reporter gene (pCMV-eGFP, 
4.7 kb, cat no. 6085-1) was obtained from Clontech (Palo Alto, CA). Qiagen Endofree 
Plasmid Giga Kit was purchased from Qiagen (Valencia, CA). 
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Polymer Synthesis 
Four sets of polymers (P-OE/M, P-3E/M, P-7E/M, P-14E/M) (Table III-l) were 
synthesized by reacting AEPZ with TMPTA (OE/M), TMPETA (3E/M), TMPETA 
(7E/M), and TMPETA (14E/M) using a synthetic approach published previously87. 
Table III-l Polymer composition and structures of the triacrylate and amine monomer 
building blocks. P-OE/M, P-3E/M, P-7E/M and P-14E/M vary in hydrophilic spacer 
length. 1 = m = n = 1 for TMPETA (3E/M), 1 + m + n = 7 for TMPETA (7E/M) and 1 + m 
+ n = 14 for TMPETA (14E/M). 
Group 
P-OE/M 
Triacrylate Monomer 
P-3E/M 
P-7E/M 
P-14E/M 
TMPTA 
TMPETA (3E/M) 
TMPETA (7E/M) 
TMPETA (14E/M) 
Amine Monomer 
o 
NH2 
AEPZ 
H 
o 
N s 
NH2 
AEPZ 
Q 
S 
NH2 
AEPZ 
H 0 
N s 
NH2 
AEPZ 
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All polymers were synthesized at a 2:1 molar ratio of amine to triacrylate 
monomer, which is the same ratio applied previously in the synthesis of polymers with 
similar architecture and polymerization mechanism87'90'91. Typically, 10.8 mmole of the 
amine monomer and 5.4 mmole of the triacrylate monomer were dissolved in 20 mL of 
chloroform in a round bottom flask. The solution was allowed to react for 8 days at 
ambient temperature. The polymer was then purified by precipitation in 400 mL of 
acetone and 5 mL of hydrochloric acid (HC1) (12 M). The product was washed with 
excess acetone and vacuum dried to remove any remaining solvent. The NMR spectra 
revealed the following characteristic signal: P-OE/M: 0.9 ppm (t, C-CH2-CH3), 1.4 ppm 
(m, O-CHr-CUj), 2.5-3.5 ppm (t, -CH2-Cft2-NR2- and t, -CH2-G£6-COO-CH2-), 
4.0-4.1 ppm (s, C-C//2-OOC-CH2-). P-3E/M, P-7E/M and P-14E/M: 0.9 ppm (t, C-
CH2-C//3), 1.4 ppm (m, C-CH2-CR3), 2.5-3.5 ppm (t, -CH2-C#2-NR2- and t, -CH2-
CH2-COO-CH2-), 3.6-3.9 ppm (s, C-CHr-O- and t, -O-CH2-CH2-O-), 4.0-4.1 ppm (t, 
-CH2-GF/H30C-CH2-). 
Polymer Characterization 
Proton Nuclear Magnetic Resonance C'H-NMR") 
'H-NMR spectra of the polymers were obtained using a 400 MHz Bruker 
spectrometer (Bruker Avance 400, Zurich, Switzerland). The samples were dissolved in 
D20 and analyzed using MesRe-C, an NMR processing software package (Mestrelab 
Research S. L., Spain). The proton peak of deuterium protium oxide (HDO) was used as 
the internal shift reference (5 = 4.8 ppm). 
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Molecular Weight Determination by Size Exclusion Chromatography (SEC) 
The weight average molecular weight (Mw), number average molecular weight 
(Mn) and polydispersity index (PDI) (Mw/Mn) of the polymers were obtained using a 
Waters Alliance® HPLC system (Waters, Milford, PA) equipped with a differential 
refractometer. The samples were run through a Shodex OHpak SB-G (6.0 x 50 mm) 
guard column, a Shodex OHpak SB803 HQ (8.0 x 300 mm) and a Shodex OHpak 
SB802.5 HQ (8.0 x 300 mm) analytical column placed in series. PEG standards with Mn 
on 
ranging from 102 to 82,500 Da were used to generate the calibration curve . A 0.5 M 
sodium acetate buffer containing 0.1 M sodium nitrate was used as the mobile phase (pH 
4.5). The flow rate was set to 0.5 mL/min, with the temperature of the column and sample 
chamber set at 25°C and 12°C, respectively. The polymer samples were dissolved in the 
mobile phase and filtered through a 0.2 urn cellulose filter (Alltech, Deerfield, IL). Data 
analysis was performed using the Empower™ software (Waters, Milford, PA) provided 
with the instrument. The theoretical average compositions of the polymers were 
calculated based on the Mn values obtained from SEC by assuming that the reaction 
occurred at the molar feed ratio of amine to triacrylate monomers of 2:1. 
Hydrogen Ion Titration 
The number of amine equivalents in a given mass of polymer was evaluated by 
hydrogen ion titration. In a typical experiment, 50 mg of polymer were dissolved in 10 
mL of 150 mM sodium chloride (NaCl) solution. The polymer solution was adjusted to a 
pH of 2.0 using 0.1 or 1 M HC1 solution and/or 0.1 N sodium hydroxide (NaOH) solution. 
The polymer solution was then titrated by stepwise (200 uL) addition of 0.1 N NaOH 
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under continuous stirring. The pH of the solution was measured after each addition of 0.1 
N NaOH solution using an accumet* AP63 Portable pH meter (Fisher Scientific, 
Pittsburgh, PA). Each titration was done in triplicate, and average pH values were 
calculated and reported. The amine equivalents (which corresponds to the amount of 
amines in the polymer) that dissociated in different pH ranges were determined by 
calculating the amounts of hydroxide ion (OH") that were required to change between two 
pH values . 
Polymer Degradation by ^-NMR Analysis 
The rate of hydrolytic ester degradation of the polymers was determined at pH 5.0 
and 7.4 by ^-NMR analysis87'115'116. In a typical experiment, a polymer sample (7.5 mg) 
was dissolved in 750 uL of pH 5.0 or 7.4 Fisher Certified Buffer117. Throughout the 
degradation study, the samples were incubated at 37°C while shaking at 75 rpm. At 
predefined time points (0 h, 6 h, 12 h, 1 d, 3 d, 7 d and 14 d), the samples were frozen and 
lyophilized. The dried samples were then dissolved in D2O and analyzed by 'H-NMR. 
This study was done in triplicate (n=3). At each time point, percent ester degradation was 
obtained by evaluating the change in the ratio of the integral of the methylene protons in 
the a-position to the ester to the integral of the methyl protons in the triacrylate 
monomers in the polymers (I4.2/I1.6). The integral of the protons in the a-position to the 
ester decreased as the esters degraded. The integral attributed to the methyl protons in the 
polymers remained unchanged during the hydrolytic ester degradation process. Equation 
1 was used to calculate the percentage of ester that was degraded at each time point, and 
on I 1c 1 1 A 
the data was reported as percent ester degraded ' ' . 
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n/ ^ ^ , , (Ratio at Oh-Ratio at time point) „, , n„ _ . 
% Ester Degraded = - - * 100 (Equation 1) 
RatioatOh 
Cytotoxicity Analysis by MTT Assay 
1 1 8 
The cytotoxicity of the polymers was evaluated using an MTT viability assay . 
CRL 1764 rat fibroblasts were expanded in T-75 culture flasks with DMEM 
supplemented with 10% (v/v) FBS and antibiotics (100 ug/mL penicillin, 100 U/mL 
streptomycin, and 0.5 ug/mL amphotericin B) and cultured at 37°C in 5% CO2 and 95% 
relative humidity. Typically, rat fibroblasts were trypsinized with trypsin-EDTA solution 
(2 mL/flask) and replated on 96-well plates with a density of 8000 cells/well. The plates 
were incubated (37°C in 5% C02 and 95% humidity) for 24 hours to allow the cells to 
reach 80-90% confluency. Polymer solutions with a pH of 7.4 and an osmolality of 280-
320 mosm/kg were prepared in DMEM at six polymer concentrations (10, 50, 100, 250, 
500 and 1000 ug/mL). Branched PEI (25 kDa) at the same concentrations was used as a 
negative control. PEI 25 kDa has been extensively characterized in the literature and is 
on 1 1 n 
often used as a control in the development of polymers for non-viral gene delivery ' . 
As cytotoxicity and transfection efficiency can vary depending on the cell type and 
source, PEI was included in this study for experiments that involved cells (i.e., 
cytotoxicity and transfection efficiency experiments) to allow for direct comparison with 
the synthesized polymers under the same conditions. To start the experiment, culture 
media was removed and 100 uE of the polymer solution was added to individual wells of 
the 96-well plates. The plates were then incubated for 2 and 24 h at 37°C. At each time 
point, the polymer solution was removed, and the wells were washed twice with PBS to 
remove any residual polymer solution. 100 uE of MTT solution (1 mg/mL in phenol red 
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free DMEM) was added to each well. After 3 h of incubation under exclusion of light, the 
MTT solution was removed and 100 uL of DMSO/2-propanol 1:1 (v/v) solution was 
added to each well to dissolve the formazan crystals formed by the live cells. The plates 
were agitated to help dissolve the formazan crystals. The absorbance was measured at 
570 nm using a microplate reader (Powerwave X340, BIO-TEK Instruments, Winooski, 
VT). The cell viability was obtained by normalizing the absorbance of the wells 
containing cells cultured in the presence of polymer solution to the absorbance of the 
wells cultured with plain media. The average number of live cells was calculated from 5 
different samples. 
Polymer/pDNA Polyplex Characterization 
Amplification and Purification of Plasmid DNA 
pCMV-eGFP was amplified in Escherichia coli (E. coli) bacterial cultures and 
purified using a Qiagen Endofree Plasmid Giga Kit according to the protocols provided 
by the manufacturer. The yield of the pDNA was determined from the UV absorbance at 
a wavelength of 260 nm (A26o) (NanoDrop™ 1000 Spectrophotometer, Thermo Scientific, 
Wilmington, DE). To evaluate the plasmid purity, the ratio of the UV absorbance at 
wavelengths of 260 nm and 280 nm (A260/A280) was determined to be between 1.8 and 
2.0. The pCMV-eGFP was used in all the polymer/pDNA polyplex characterization 
experiments. 
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Zeta Potential 
Polymer/pDNA polyplexes were prepared at different polymer to pDNA weight 
ratios (5:1, 10:1, 50:1, 100:1, 200:1 and 300:1). The polyplexes were prepared by adding 
various amounts of polycationic polymer solution in PBS (300 uL) drop-wise to 10 jag of 
pDNA also dissolved in 300 uL PBS. The mixture was vortexed and then incubated for 1 
h at room temperature to allow for polyplex formation. The zeta potential of the resulting 
particles or larger aggregates was obtained using a Zen 3600 Zetasizer (Malvern 
Instruments, Worcestershire, UK). Disposable cuvettes were filled with the polyplex 
solution and run in the zetasizer for a minimum of 10 cycles and a maximum of 100 
cycles at 25°C. The zeta potential was calculated using the Smoluchowski equation 
based on the electrophoretic mobility . This study was done in triplicate. 
Band Retardation with Gel Electrophoresis 
Different weight ratios (10:1, 20:1, 30:1, 40:1, 60:1, 80:1 and 100:1) of 
polycationic polymer to pDNA solutions were prepared. The polyplexes were prepared 
from 10 (J.L polymer solution in PBS and 10 ul of a solution of 1 |xg pDNA in PBS as 
described above. A 0.5% (w/w) of agarose gel containing 5 uL of ethidium bromide 
solution (10 mg/mL) was prepared in TAE buffer (lx). The polyplex sample (20 uL) 
containing bromophenol blue loading solution was loaded into the wells. The gel was run 
for 1 h at 80 mV in TAE buffer (lx) and an image of the gel was captured in an UV 
transillumination box. 
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Hydrodynamic Polyplex Sizes by Dynamic Light Scattering (DLS) 
The hydrodynamic diameter of the polycationic polymers/pDNA polyplexes was 
evaluated at different polymer to pDNA weight ratios (10:1, 50:1, 100:1, 200:1, 300:1 
and 500:1) using a 90PLUS Particle Size Analyzer (Brookhaven Instruments Corporation, 
Holtsville, NY) with an incident beam of 660 nm wavelength and scattering angle set at 
90°. The data were collected using the BIC 32 Bit Software (Brookhaven Instruments 
Corporation, Holtsville, NY). The polyplexes were prepared from 300 uL polymer 
solution in PBS and 300 uL of a solution of 10 ug pDNA in PBS as described above. The 
solution was allowed to equilibrate to 25°C inside the analyzer before the analysis was 
started. The diameter of the polyplexes or aggregates thereof was obtained using Laplace 
inverse program Non-Negative Least-Squares (NNLS)119. This study was done in 
triplicate. 
eGFP Transfection of Rat Fibroblasts 
CRL 1764 rat fibroblasts were grown in T-75 culture flasks using DMEM 
supplemented with 10% (v/v) FBS and antibiotics (100 ug/mL penicillin, 100 U/mL 
streptomycin, and 0.5 ug/mL amphotericin B) at 37°C in an incubator (5% CO2, 95% 
relative humidity). In a typical experiment, rat fibroblasts were trypsinized (2 mL trypsin-
EDTA solution/flask) and replated in 6-well plates at a seeding density of 250,000 
cells/well. After 24 h of cell attachment, media was aspirated and 100 uL of the plasmid 
polyplex solution containing 5 ug of pDNA complexed at different polymer/pDNA 
weight ratios (10:1, 50:1, 100:1, and 300:1) was added drop-wise to the cells. The 
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following solutions served as controls: PEI/pDNA at a weight ratio of 2:1, naked pDNA 
and FBS-free media without pDNA. The weight ratio of 2:1 for PEI/pDNA polyplexes 
corresponds to a ratio of amine groups in the polymer to phosphate groups in the pDNA 
(N:P) of 11.5:1, which is similar to that used by Wu et al. (N:P of 10:1) as the optimal 
on 
N:P for transfection with PEI . The polyplexes were prepared from 50 uL polymer 
solution in PBS and 50 [i\ of a solution of 5 ug pDNA in PBS as described before. 
Immediately after the addition of 100 u.L of the polypi ex solution, 400 uL of DMEM 
(FBS free) was added. After 24 h, 2 mL of DMEM/FBS (10% (v/v)) was added to the 
cells, and the flask was incubated for an additional 48 h. The cells were then washed 
twice with PBS, trypsinized (500 uL of trypsin-EDTA solution per well), washed with 
PBS, fixed with chilled formaldehyde solution (1%) and placed on ice for 1 h. After 
washing with PBS, samples were analyzed using a flow cytometer (Becton Dickenson 
FACS Scan, BD Biosciences, San Jose, CA) at high flow. CellQuest Pro software (BD 
Biosciences, San Jose, CA, v 5.1) was used to collect the data. A total of 5000 cells were 
counted for each sample. The location of the cells on the dot plot was confirmed by 
running untreated cells in PBS through the cytometer. Markers were placed at 5% of 
control samples (untreated cells) and the relative rightward shift of the intensity was 
observed as the percentage of transfected cells. This study was done at n=5. 
Fluorescence images of selected samples were taken with a confocal microscope (Zeiss 
LSM 510, Carl Zeiss Jena, Germany) to confirm transfection and expression of the green 
fluorescent protein. The cells were imaged with a 20x objective after excitation by an 
argon laser. The transfection study was designed to ensure that a lower mass of polymer 
per unit area of culture well compared to that tested in the cytotoxicity experiment was 
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used. In the cytotoxicity experiment, cells exposed to the highest mass of polymer per 
unit area of culture well tested, 300 \ig/cm2 (polymer concentration of 1000 fig/mL), were 
still viable. In the transfection experiment, the highest mass of polymer per unit area of 
culture well that was tested was 150 u.g/cm2 (weight ratio of 300:1). 
Statistical Methods 
The results were presented as means ± standard deviation. Single-factor analysis 
of variance (ANOVA) was used to identify if there were any significant differences 
among groups (p < 0.05). Tukey's Honestly Significantly Difference (HSD) test was then 
conducted to identify the specific groups that differed statistically significantly. 
Results and Discussion 
Polymer Synthesis 
Polymers were synthesized and precipitated from acetone through the addition of 
HC1. The precipitates were solid or rubbery and sticky. The protonated polymers were 
insoluble in organic solvents, thus all characterizations were done in aqueous solutions. A 
general structure of the synthesized branched polymers is shown in Figure III-1. The end 
groups in the polymer are primary amines from the amine monomer, AEPZ, that did not 
react with the triacrylate monomer . Once protonated, these primary amines can 
participate in the complexation with pDNA. The yields of the polymerization were 
between 70-85%. 
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Figure III-l General structure of a branched polymer obtained by Michael addition 
reaction of AEPZ with a triacrylate monomer. 
Polymer Characterization 
Proton Nuclear Magnetic Resonance (^H-NMR) 
'H-NMR confirmed that all acrylate groups of the triacrylate monomers converted 
during the reaction, as the typical signals for olefinic protons (5.8-6.6 ppm) were absent 
for the polymeric products (not shown). Since the presence of unreacted acrylate groups 
would contribute to polymer cytotoxicity, it is important to achieve complete reaction of 
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the acrylate groups . 
'H-NMR data was also used to verify that the polymer building blocks, amine and 
triacrylate monomers, reacted in a molar ratio of 2:1. The integral of the peaks between 
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2.5-3.5 ppm (derived from six protons: -CH2-C//2-NR2 in the amine monomer, -CH2-
C//2-NR2 formed through the reaction, and -GHV-COO-CH2- from the triacrylate 
monomer) was compared to the integral of the peak at 0.9 ppm (derived from three 
methyl protons in the triacrylate monomers). These calculations yielded molar ratios for 
P-OE/M, P-3E/M, P-7E/M and P-14E/M of 1.8, 2.1, 1.9, and 2.3, respectively. 
Molecular Weight Determination 
Table III-2 presents Mn, Mw and PDI of the polymers as obtained by SEC, as 
well as the theoretical average composition of the polymers calculated based on the 
experimental Mn and Mw values. 
Table III-2 Number average molecular weight, weight average molecular weight, 
polydispersity index (PDI), estimated average number of triacrylate and amine monomers 
per polymer molecule and pKa values of the polymers examined in this study. 
Number of 
Amine pKa 
Monomers 
8 (20) 7.85 
6(14) 7.93 
6 (20) 8.02 
6(18) 8.08 
* Measured by size exclusion chromatography 
Estimated from number average molecular weight, numbers in brackets estimated from 
weight average molecular weight 
Polymer 
P-OE/M 
P-3E/M 
P-7E/M 
P-14E/M 
Mn (Da)* 
2,700 
1,980 
2,310 
3,180 
Mw (Da)* 
6,670 
4,800 
8,660 
10,070 
PDI* 
2.47 
2.42 
3.75 
3.17 
Number of 
Triacrylate 
Monomers 
4(10) 
3(7) 
3(10) 
3(9) 
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The SEC traces of the synthesized polymers are shown in Figure III-2. It was found that 
on average the polymers consisted of 6 or 8 amine and 3 or 4 triacrylate monomers. Low 
molecular weights were obtained for the synthesized polymers. The molecular weights of 
the polymers were obtained with SEC using linear PEG standards to generate the 
calibration curve. The calibration with a linear polymer may not account for the effect of 
branching that may be present in the polymers; thus an underestimation of the molecular 
weights may have occurred. 
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Figure III-2 Size exclusion chromatography traces of the synthesized polymers. 
As the variable in this study (i.e., hydrophilic spacer length) was altered, the 
molecular weight and degree of branching in the polymers were potentially affected as 
well. The molecular weight (Mn and Mw) of the polymers was found to increase with the 
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hydrophilic spacer length of the triacrylate monomer (P-14E/M > P-7E/M > P-3E/M). P-
OE/M, which was synthesized from the smallest acrylate precursor (TMPTA), showed 
comparably high molecular weights and a low PDI and consisted on average of 1 
triacrylate and 2 amine monomers more than the other polymers. Although there was an 
increase in molecular weight as the hydrophilic spacer increased, all the polymers were 
formed from a similar amount of amine and triacrylate monomer (Table III-2). Thus, a 
large effect of degree of branching on the parameters and polymers investigated in this 
study is not expected. The difference in Mw likely resulted from the difference in the 
mass of the triacrylate monomer (i.e., molecular weight of monomer increases with the 
increase in hydrophilic spacer length) rather than from the amount of potential branching 
in the polymers. Although this study provided initial insight on the effects of the 
hydrophilic spacer lengths, further investigation will facilitate a more complete 
understanding of the individual effects of the various parameters (hydrophilic spacer 
length, polymer MW and degree of branching). 
Determination of Amine Equivalents and Polymer pKa Values by Hydrogen Ion Titration 
Hydrogen ion titration of the polymers was conducted from pH 2 to pH 12, 
instead of from pH 12 to pH 2, to avoid degradation of the polymers at basic pH. The 
titration curves obtained are shown in Figure III-3. Table III-2 lists the pKa values 
determined for the polymers. For the amine monomer AEPZ, which contains a primary, 
secondary and tertiary amine, a pKa value of 9.30 was obtained. 
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Figure III-3 Titration curves (0.1 N NaOH) of the polymers. The results are expressed as 
means ± standard deviations for n=3. 
The pKa values of the amines changed upon conversion in the addition reaction. 
During the Michael-type reaction the alkyl substitution of the amines is increased, i.e., a 
primary amine becomes secondary and a secondary amine becomes tertiary. Besides 
increased alkyl substitution, sterically hindered accessibility also contributes to the 
observed changes in amine pKa. The synthesized polymers displayed pKa values in a 
small range between 7.85 and 8.08. pKa values of the polymers increased with the 
hydrophilic spacer lengths in the triacrylate monomers, likely due to improved 
accessibility of the amines. The titration curves for the four synthesized polymer types 
were very similar in shape (Fig. III-3) which was expected because they all consist of the 
same amine monomer (Table III-l). The polymers in this study were synthesized from an 
amine monomer, AEPZ, that has a primary, secondary and tertiary amine, where the 
QfL 0*7 
reaction occurs first at the secondary amine and then at the primary amine ' . The 
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synthesized polymers have amine groups that have different degrees of substitution and 
chemical environments and dissociate at different pH values. The buffering by the 
different amine groups blended into a broad buffering range, where distinct plateau and 
equivalent points for the different types of amines were not observed, which resulted in 
one pKa value for the whole polymer. Figure III-3 shows that the buffering pH ranges of 
polymers with shorter hydrophilic spacers were wider as compared to those determined 
for polymers with longer hydrophilic spacers. This indicates that polymers with shorter 
hydrophilic spacers have higher buffering capacities. 
For a given mass of polymer (typically 50 mg), the amine equivalents dissociating 
in four different ranges were evaluated (Fig. III-4). The amine equivalents that dissociate 
between pH 2.5 and 5.0 were evaluated in order to compare the availability of 
199 
unprotonated amines at pH 5.0 that may catalyze hydrolytic ester degradation . 
Similarly, the amine equivalents that dissociate between pH 2.5 and 7.4 were determined 
to compare the availability of unprotonated amines which can catalyze the hydrolytic 
ester degradation at pH 7.4. The amine equivalents that dissociate at pH 5.0 - 7.4 were 
obtained to estimate the buffering capacity of the polymers at the endosomal/lysosomal 
pH range and thus, the polymer's ability to aid in pDNA escape from the endosome prior 
to lysosomal degradation by nucleases . The amine equivalents dissociating above pH 7.4 
were calculated to determine the amounts of protonated amines that could help with 
polymer/pDNA complexation when the polyplexes are assembled at pH 7.4. 
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Figure III-4 Amine equivalents that dissociate at different pH ranges. The results 
represent means ± standard deviations for n = 3. # indicates a statistically significant 
difference between one polymer and the other polymers within the same pH interval 
(p<0.05). * represents a statistically significant difference between two polymers within 
the same pH interval (p<0.05). 
For a given mass of polymer (50 mg), polymers with shorter hydrophilic spacer 
lengths, which contain a higher density of amines per molecular weight by design, had 
higher buffering capacities between pH 5.0 and 7.4 as well as between pH 7.4 and 11.0 
(Fig. III-4). Consequently a higher number of protonated amines is available in the 
polymers with short spacer lengths to aid in pDNA escape from the endosome and for the 
assembly of polymer/pDNA polyplexes at pH 7.4. In these polymers, a comparably large 
number of unprotonated amines is available below pH 7.4 that could assist with polymer 
hydrolytic ester degradation. 
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Polymer Degradation ('H-NMR) 
In this study, the rate of hydrolytic ester degradation of the polymers, which 
occurs in the body when the polymers are exposed to the aqueous environment, was 
investigated. The hydrolytic ester degradation profiles of the polymers at pH 5.0 and 7.4 
are shown in Figures III-5A and III-5B, respectively. Figure III-5C compares the 
polymers at two time points (3 and 14 days). Polymers with longer hydrophilic spacers 
degraded faster than those with shorter spacers at both tested pH values. This is explained 
by the hydrophilic spacers attracting water molecules to the ester sites. Furthermore, 
polymers with longer hydrophilic spacers likely form looser structures with more flexible 
chains and more easily accessible ester sites . Comparing the polymers synthesized from 
the different triacrylate monomers, the amount of ester degraded increased as the length 
of hydrophilic spacer increased. P-3E/M had a significantly higher amount of esters 
degraded compared to P-7E/M and P-14E/M at pH 5.0 after 3 and 14 days. At pH 7.4, P-
3E/M had a significantly higher amount of esters degraded compared to P7E/M and P-
14E/M after 3 days, however the amount of ester degraded in the three TMPETA 
polymers were not significantly different after 14 days. The amount of esters degraded 
for P-OE/M (no spacer) and P-14E/M (longest spacer) were significantly different from 
each other at day 14. The percent of ester degraded increased from 43.4 ± 2.1% to 55.7 ± 
2.6% at pH 5.0 and 89.7 ± 1.3% to 98.5 ± 1.6% at pH 7.4 with the increase in hydrophilic 
spacer length. P-OE/M, which was synthesized from TMPTA and contained no 
ethyleneoxy groups, degraded faster than P-3E/M for most of the time points and 
conditions observed. Due to its lower molecular weight compared to P-OE/M, P-3E/M 
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Figure III-5 Ester degradation profiles of the polymers at 37°C and (A) pH 5.0 
simulating lysosomal pH and (B) pH 7.4 simulating cytoplasmic pH and (C) degree of 
degradation after 3 and 14 days at pH 5.0 and 7.4 at 37°C as observed by ^-NMR. The 
extent of degradation is expressed as means ± standard deviation for n = 3. # indicates a 
statistically significant difference between one polymer and the other polymers degraded 
under the same conditions (p<0.05). * represents a statistically significant difference 
between two polymer compositions degraded under the same conditions (p<0.05). 
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chains may have formed tighter structures and their ester groups might have been more 
effectively shielded from hydrolytic degradation. In summary, hydrophilic spacers can be 
incorporated into the polymers to increase their hydrolytic degradation rates. All 
polymers showed a higher rate of hydrolytic ester degradation at pH 7.4 (cytoplasmal pH) 
than at pH 5.0 (lysosomal pH). This is explained by a higher number of unprotonated 
amine groups that are present at the higher pH to catalyze hydrolysis of the ester groups, 
which is consistent with previous work on poly(ester amine)s79'122. Olefmic protons (5.8-
6.6 ppm), which would contribute to polymer cytotoxicity , were not present in the H 
NMR spectra of polymer degradation samples over the course of the hydrolytic ester 
degradation study (data not shown), indicating that a reverse Michael addition reaction, 
which would yield free acrylate groups, did not occur. 
Cytotoxicity Analysis 
Cells remained viable after incubation with polymer solutions for 2 and 24 h at all 
concentrations tested. PEI, which was tested in comparison, however, caused significant 
cell death (Fig. III-6). After 2 h, more than 70% of the cells exposed to the polymers with 
different hydrophilic spacers were viable (Fig. III-6A). After 24 h, more than 70% of the 
cells were viable except for the cells that were exposed to P-3E/M at 1000 \ig/mL 
concentration (66.9 ± 12.1% viability) (Fig. III-6B). In general, polymers with longer 
hydrophilic spacers (P-7E/M and P-14E/M) were less cytotoxic as compared to those 
with shorter or no spacer (P-0E/M and P-3E/M) after 24h. This is likely due to the 
decrease in the charge density in the polymers . 
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Figure III-6 Cytotoxicity of the polymers (with polyethylenimine (PEI) as negative 
control) on CRL 1764 rat fibroblasts after (A) 2 h and (B) 24 h as evaluated by an MTT 
assay. The results are expressed as means ± standard deviation for n = 5. 
The slow degradation rates observed for P-OE/M and P-3E/M may also contribute to the 
observed toxicity111. PEI, in contrast, caused significant cell death after 2 h with less than 
25% cell viability at a concentration of 250 [ag/mL or higher. After 24 h, less than 8% of 
the cells were viable when exposed to PEI at a concentration of 50 |j,g/mL or higher. PEI 
has an 8-13 times higher molecular weight and 2-3 times higher charge density compared 
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to the synthesized polymers. Both parameters certainly contribute to the high toxicity of 
PEI '124. The improved cytocompatibility of the developed polycationic polymers will 
allow for use at high concentrations and high N:P ratios. 
Polymer/pDNA Polyplex Characterization 
Zeta Potential 
The surface charge of the polyplexes formed by the polymers was evaluated to 
determine optimal polymer to pDNA ratios, which result in a positively charged polyplex 
that can interact with, instead of repulsing, the negative charges on the cell membrane59'75. 
The pCMV-eGFP plasmid, which was used in this study, has a zeta potential of -33.1 ± 
0.5 mV. All the polyplexes formed at a polymer/pDNA weight ratio of 5:1 had a negative 
zeta potential ranging from -8.5 ± 0.4 mV to -27.5 ± 2.9 mV (Fig. III-7). At a weight ratio 
of 10:1, P-OE/M, P-3E/M and P-7E/M formed polyplexes that were neutral. P-14E/M, 
which of all tested polymers provides the least amines per molecule and therefore will 
form polyplexes at the lowest N:P ratio at a given weight ratio of polymer to DNA, 
formed a negative polyplex (-4.3 ±1 .9 mV) at a weight ratio of 10:1 and a positive 
polyplex (7.3 ± 0.5 mV) at a weight ratio of 50:1. The zeta potential of all the polyplexes 
formed increased as the weight ratio of polymer to pDNA increased, which corresponds 
with the changing N:P ratios within the polyplexes. Consequently, the polyplexes formed 
from polymers with shorter hydrophilic spacer lengths had higher zeta potentials 
compared to polyplexes with polymers with longer hydrophilic spacers at all tested 
weight ratios. 
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Figure III-7 Zeta potential of the polyplexes formed with 10 ug pCMV-eGFP DNA at 
different polymer/pDNA weight ratios. The results are expressed as means ± standard 
deviation for n = 3. # indicates statistically significant difference between a polyplex and 
other polyplexes in the same weight ratio (p<0.05). * represents a statistically significant 
difference between two polyplexes within the same weight ratio (p<0.05). 
Band Retardation with Gel Electrophoresis 
The electrophoretic patterns of the polymer/pDNA polyplexes were obtained by 
gel electrophoresis in agarose gel and UV light detection (Fig. III-8). Lane 8 in all images 
represents uncomplexed pDNA (naked pDNA) and shows migration of the plasmid to the 
positive end of the gels. P-OE/M, P-3E/M and P-7E/M were able to retard the migration 
of the pDNA at polymer/pDNA weight ratios of 10:1 and higher. 
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Figure III-8 Gel retardation assay of pDNA/polymer polyplexes at different 
polymer/pDNA weight ratios: (1) 100:1, (2) 80:1, (3) 60:1, (4) 40:1, (5) 30:1, (6) 20:1, (7) 
10:1, and (8) naked pDNA. 
In correspondence with the zeta potential results (Fig. III-7), the polymers 
neutralized the charges of the pDNA at a ratio of 10:1. At these ratios, zeta potential 
measurements revealed neutrality of the polyplexes, which favors particle aggregation as 
electrostatic repulsion is minimal. The zeta potential of P-14E/M was negative at a 
weight ratio of 10:1 and positive at a ratio of 50:1. Neutral polyplexes are consequently 
expected within this range. Through gel electrophoresis, P-14E/M was found to retard the 
migration of pDNA at weight ratios of 20:1 or higher. The higher amount of P-14E/M 
needed to neutralize the charges on the pDNA is explained by the low molar content of 
amine groups. 
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Hydrodynamic Polyplex Sizes by Dynamic Light Scattering (DLS) 
The hydrodynamic size (diameter) of the polyplexes formed by the polymers and 
pDNA at different weight ratios was obtained by DLS (Fig. III-9). At low 
polymer/pDNA weight ratios (10:1 for all the polymers, also 50:1 for P-OE/M), 
aggregation of the polyplexes was observed as shown by large particle diameters ranging 
between 923.4 ± 75.6 nm and 1910.5 ± 17.2 nm. 
P-OE/M • P-3E/M 0 P-7E/M P-14E/M 
10:1 50:1 100:1 200:1 300:1 
Polymer/pDNA Weight Ratio 
500:1 
Figure III-9 Diameter of the polyplexes formed with 10 (xg pCMV-eGFP DNA at 
different polymer/pDNA weight ratios as evaluated by DLS. The results are expressed as 
means ± standard deviation for n = 3. # indicates statistically significant difference 
between a polyplex and other polyplexes in the same weight ratio (p<0.05). * represents a 
statistically significant difference between polyplexes within the same weight ratio 
(p<0.05). 
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The zeta potential increased as the polymer/pDNA ratios were increased (Fig. III-7) and 
individual polyplexes were electrostatically stabilized54. Consequently, the diameters of 
the polyplexes decreased to 147.2 ± 14.1 nm (P-7E/M, polymer/pDNA weight ratio of 
300:1). Naked pDNA, in comparison, had a diameter of around 751.6 ± 111.8 nm (data 
not shown). The results indicate that all the polymers were able to complex with and 
condense the pDNA at certain weight ratios, which is essential for DNA stabilization and 
transfection efficiency73. Although the polyplexes formed with the polymers developed in 
this study may not be as small as those formed by branched PEI (25 kDa) (-20-40 nm)125, 
the polyplexes formed with the polymers developed in this study are promising, as larger 
sized particles have been found to sediment onto cells, increasing the interaction with the 
cells, which can enhance particle uptake57'126. Larger polyplexes may not get internalized 
through clathrin coated endocytosis54, however they have been shown to get internalized 
successfully by other mechanisms which have not been elucidated57'58. 
Transfection Efficiency with Enhanced Green Fluorescent Protein Reporter Gene 
The results from the transfection study are shown in Figure III-10. At low 
polymer/pDNA weight ratios (10:1 and 50:1), only P-3E/M resulted in a significantly 
higher number of transfected cells than naked pDNA. At a polymer/pDNA weight ratio 
of 100:1, P-0E/M, P-3E/M and P-14E/M resulted in significantly higher transfection rates 
(7.2 ± 0.5% to 8.0 ± 1.5%) than naked pDNA (0.8 ± 0.4%). At the highest weight ratio 
(300:1), P-0E/M, P-3E/M and P-7E/M resulted in significantly higher transfection (6.7 ± 
2.0%) to 9.4 ± 2.0%>) than naked pDNA. The transfection efficiency of polyplexes formed 
at weight ratios 100:1 and 300:1 were not significantly different from each other. Above 
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a certain weight ratio, no increase in surface charge (Fig. III-7) or reduction in the size 
(Fig. III-9) of the polyplexes formed were observed within a polymer group, as also 
observed in a study by Wu et al.87. 
• Naked DNA El PEI (2:1) • P-OE/M 
• P-3E/M 0P-7E/M BP-14E/M 
10:1 50:1 100:1 300:1 
Polymer/pDNA Weight Ratio 
Figure 111-10 Efficiency of CRL 1764 cell transfection with polyplexes formed with 5 
(xg pCMV-eGFP DNA at different polymer/pDNA weight ratios. Naked pDNA and 
polyplexes formed from PEI at a polymer/pDNA weight ratio of 2 served as controls. The 
results are expressed as means ± standard deviation for n = 4-6. # indicates a statistically 
significant difference between a polyplex and naked pDNA (p<0.05). 
This suggests that at a certain polymer/pDNA weight ratio, the amount of polymer that 
participates in the polyplex formation may reach a critical point where any polymer 
subsequently added to the polyplex solution will remain uncomplexed. Thus, above that 
critical point, the addition of polymer will not facilitate additional complexation. 
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Determination of the amount of uncomplexed polymer was not part of the design of this 
study. However, quantification of the amount of uncomplexed polymer in the future will 
give more insight on the polymer/pDNA complexation. 
At all the weight ratios tested, the percent of cells transfected by polyplexes made 
from the synthesized polymers was significantly lower than obtained for polyplexes with 
PEI at a weight ratio of 2:1. The low molecular weights and charge densities of the 
synthesized polymers as compared to PEI are factors explaining the lower transfection 
efficiencies observed ' . Although low transfection efficiencies were observed in vitro 
for the synthesized polymers under the conditions explored in this study, they were 
higher at certain weight ratios than those associated with naked pDNA. 
Fluorescence micrographs were taken to confirm the transfection results obtained 
by flow cytometry. As a negative control, a fluorescence image of cells treated with just 
media was taken (Fig. III-l 1 A). There were no transfected cells observed when exposed 
to naked pDNA (Fig. III-l IB). Cells transfected with polyplexes of P-OE/M at a 
polymer/pDNA weight ratio of 300:1 had overall faint eGFP expression as seen in Figure 
III-l 1C. Arrows point to cells that expressed eGFP. Cells that were transfected with 
PEI/pDNA (2:1) polyplexes had a more intense expression of eGFP (Fig. III-l ID). 
A very low number of live cells, however, were observed after exposure to PEI 
polyplexes, as seen by light microscopy (data not shown). The cytotoxicity of PEI is well 
described in the literature and likely attributed to the high MW and charge density of 
PEI123. Wells treated with the polymers synthesized in this study, even at polymer/pDNA 
weight ratios as high as 300:1, revealed a high number of live, well spread cells as seen 
by light microscopy. 
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The results indicate that the synthesized polycationic polymers degrade well 
under physiological and lysosomal conditions and can efficiently complex pDNA and 
transfect cells. 
Figure III- l l Representative fluorescence images of CRL 1764 cells after exposure to 
the following media: (A) plain medium, (B) naked pDNA (CMV-eGFP), (C) P-
OE/M/pDNA (300:1), and (D) PEtfpDNA (2:1). An amount of 5 ug pCMV-eGFP DNA 
was used for each media consisting of pDNA (B-D). Green fluorescence in cells 
represents expression of GFP. Brightly fluorescing cells are indicated by arrows. Scale 
bars represent 50 um. 
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As a result of the low molecular weight of the polymers and the lower charge density 
than PEI, effective DNA complexation is achieved at high N:P ratios, and the transfection 
efficiencies are comparably low. At the same time, these parameters contribute to the low 
cytotoxicity of the developed polymers, which makes them potential vectors for non-viral 
gene delivery applications. This study suggests that the polymers can be used at higher 
concentrations compared to PEI and for repeated dosage. 
In this study, a limited effect of hydrophilic spacer length on the transfection 
efficiency of the polymers was observed. However, there were other parameters, such as 
degradation rate, which were significantly affected by the length of the hydrophilic 
spacers. In this study, the cells were directly exposed to the polyplexes, but for in vitro or 
in vivo gene therapy approaches where the polyplexes are first released from a scaffold, 
the polyplexes may take a longer time to reach the cells. Thus, the significant differences 
in degradation rates of polymers with different spacer lengths may result in pDNA being 
released at different times and in different forms (i.e., intact complexes or free pDNA), 
which could in turn result in significant differences in transfection. Rat fibroblasts were 
chosen as an initial model cell line in this study, and transfection was performed in the 
absence of serum; however, transfection efficiency can vary between cell lines and with 
the absence or presence of serum. Future transfection studies in vitro in different cell 
lines as well as in vivo in an appropriate animal model will yield a more comprehensive 
analysis of the transfection capabilities of these polymers. 
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Conclusions 
This study confirmed our hypothesis that the introduction of hydrophilic spacers 
to branched biodegradable polycationic polymers yields effective gene delivery vectors 
with reduced cytotoxicity and increased polymer degradation rates. Polymers with shorter 
hydrophilic spacers yielded polyplexes with higher N:P ratios, which resulted in 
polymer/pDNA polyplexes with higher zeta potentials. The percent of cells transfected by 
polyplexes of the synthesized polymers at certain weight ratios was significantly higher 
than that associated with naked pDNA, however, not comparable to polyplexes with 
branched PEI with a weight ratio of 2:1. The lower transfection observed could have 
resulted from the lower molecular weight and reduced charge density of these polymers 
compared to PEI. However, a higher density of cells was observed after exposure to the 
synthesized polymers at high concentration, indicating the capability of the polymer to be 
used at high concentration as needed for transfection with these polymers. Further work 
will be done to optimize the Michael addition synthesis to produce polymers with higher 
molecular weight to study the effect of molecular weight on transfection. The findings of 
this work can be used for the design of non-viral vectors with tailored structural and 
degradative characteristics as needed for specific applications. 
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CHAPTER IV 
SYNTHESIS AND CHARACTERIZATION OF BIODEGRADABLE BRANCHED POLYCATIONIC 
POLYMERS WITH VARYING AMINE BASICITIES FOR NON-VIRAL GENE DELIVERY* 
Abstract 
In this work, biodegradable branched polycationic polymers were synthesized by 
Michael addition polymerization from different amine monomers and the triacrylate 
monomer trimethylolpropane triacrylate. The polymers varied in the amount of amines 
that dissociate in different pH ranges, which are considered to be beneficial to different 
parts of the gene delivery process. P-DED, a polymer synthesized from 
trimethylolpropane triacrylate and dimethylethylenediamine, had the highest number of 
protonated amines that are available for plasmid DNA (pDNA) complexation at pH 7.4 of 
all polymers synthesized. P-DED formed a positive polyplex (13.9 ± 0.5 mV) at a 
polymer/pDNA weight ratio of 10:1 in contrast to the other polymers synthesized, which 
formed positive polyplexes only at higher weight ratios. Polyplexes formed with the 
synthesized polymers at the highest polymer/pDNA weight ratio tested (300:1) resulted 
in higher transfection with enhanced green fluorescent protein reporter gene (5.3 ± 1.0% 
to 30.6 ± 6.6%) compared to naked pDNA (0.8 ± 0.4%), as quantified by flow cytometry. 
Polyplexes formed with P-DED (weight ratio of 300:1) also showed higher transfection 
(30.6 ± 6.6%o) as compared to polyplexes formed with branched polyethylenimine 
(weight ratio of 2:1, 25.5 ± 2.7%). The results from this study demonstrated that 
+This chapter has been published as follows: S.A. Chew, M.C Hacker, A. Saraf, R.M. Raphael, F.K. 
Kasper, and A.G. Mikos, Altering Amine Basicities in Biodegradable Branched Polycationic Polymers for 
Non-Viral Gene Delivery, Biomacromolecules, 11, 600-609 (2010). 
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polymers with amines that dissociate above pH 7.4, which are available as positively 
charged groups for pDNA complexation at pH 7.4, can be synthesized to produce stable 
polyplexes with increased zeta potential and decreased hydrodynamic size that efficiently 
transfect cells. This work indicated that polymers containing varying amine 
functionalities with different buffering capabilities can be synthesized by using different 
amine monomers and used as effective gene delivery vectors. 
Introduction 
Polycationic polymers have been widely investigated as non-viral vectors for gene 
delivery. In contrast to viral vectors, which are known to be efficient gene carriers, 
polycationic polymers generally lack drawbacks commonly associated with viral vectors, 
such as immune response, production complexity and cost66'6 . Depending on the 
chemical structure and environment of the amine functionalities in polycationic polymers, 
these amines dissociate at different pH values resulting in pH dependent charge densities 
of the polymers. During the various steps involved in the gene delivery process, different 
buffering profiles are considered to be beneficial. For DNA complexation and polyplex 
formation, the number of amines dissociating above pH 7.4 is important, as only charged 
amines are able to electrostatically interact with the negative charges of the phosphate 
groups along the DNA backbone53'128. The process of DNA complexation aids with 
condensing and protecting plasmid DNA from degradation. An excess of positive charges 
ultimately results in the formation of positively charged polymer/DNA polyplexes, which 
can effectively adhere to target cells by interacting with the negatively charged 
phospholipids and sulfate groups of the proteoglycans on the cells ' . This interaction 
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may also improve the chance for endocytotic internalization of the polymer/DNA 
polyplexes. Upon internalization, amine functionalities that dissociate in the pH range 
between 5.0 and 7.4 play an important role, as they buffer the pH in the endosome. A 
material with buffering capacity in this pH range can assist in the escape of the DNA 
from the endosome and prevent DNA degradation by nucleases in the lysosome through 
the proton sponge effect . During the delivery process, an optimal degradation rate of 
main or side chains is another vital component of the polycationic polymer to ensure the 
release of the encapsulated pDNA and the excretion of the polymer and its side 
products81. Polymer degradation should not occur too rapidly to avoid premature 
disassembly of the DNA from the polyplex. On the other hand, the polymer should 
degrade quickly enough to facilitate DNA disassembly from the polyplex once the 
polyplex reaches the cytoplasm or nucleus, so that free DNA is available for expression 
in the nucleus . The degradation of the polymer is also beneficial in lowering the 
cytotoxicity of the polymer, as the polymer's charge density decreases when the polymer 
degrades into fragments of low molecular weight, which interact less with cell 
compartments ' . It has been shown for poly(ester amine)s that unprotonated amines 
have the capability to autocatalyze degradation . Thus, for poly(ester amine)s, amine 
groups that are in an unprotonated state at pH 5.0 (lysosomal pH) and 7.4 (cytoplasmal 
pH) play important roles during the delivery process. 
Biodegradable polycationic polymers can be synthesized by a variety of 
polymerization methods, such as Michael addition85"91'107 and reversible 
1 9Q 1 ^0 
addition-fragmentation chain transfer (RAFT) ' polymerization. Biodegradable 
polymers synthesized from acrylate and amine monomers by Michael addition 
64 
polymerization as non-viral gene delivery vectors have been previously investigated by 
many groups, including ours. The acrylate monomers can be either bifuctional85'86'88'89 or 
trifunctional 7'9 ' ' 7 yielding linear or branched poly(ester amine)s, depending on the 
type of amine monomer used during the addition reaction. The ester groups in the 
acrylate monomers allow for hydrolytic biodegradation of the polymers. In our previous 
work, we synthesized a series of polymers with different types of triacrylate monomers 
and with a single amine monomer, 1-(2-aminoethyl)piperazine (AEPZ), to investigate the 
effects of hydrophilic spacer lengths on polymer properties relevant for the gene delivery 
process . It was found that the incorporation of hydrophilic spacers into the polymers 
decreased polymer cytotoxicity and accelerated hydrolytic degradation. These alterations 
of the triacrylate monomer chemistry, however, resulted in a decrease of amine group 
density and affected the contribution of the amines to key steps of the gene delivery 
process, namely DNA complexation, endosomal escape and polymer degradation. In 
addition, variations of the hydrophilicity of the triacrylate monomers did not significantly 
affect the dissociation properties of the polymers. Consequently, this study focuses on 
altering the amine monomers used during polymer synthesis with the objective to yield 
polymers with buffering profiles and pKa values different from those investigated in our 
previous work . It is hypothesized that by changing the density, degree of substitution 
and chemical environment of the polymeric amine groups through altering the amine 
monomers used for polymer synthesis, polymer characteristics relevant for gene delivery 
can be altered and controlled. 
In this study, a series of polymers was synthesized by chemically conjugating 
different amine monomers with a single triacrylate monomer, trimethylolpropane 
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triacrylate (TMPTA), to evaluate the effects of altering amine basicities on parameters 
important for gene delivery. The specific objectives of this work were to investigate the 
effects of chemically different amine groups on characteristics of the polymer 
synthesized (molecular weight, basicity determined as amine equivalents dissociating 
within different pH ranges, degradability and cytotoxicity) and of polypi exes with pDNA 
(polyplex hydrodynamic diameter, zeta potential and transfection efficiency) to determine 
design parameters for effective non-viral gene delivery vectors. 
Materials and Methods 
Materials 
TMPTA, AEPZ, l-(3-aminopropyl) imidazole (API), N,N-
dimethylethylenediamine (DED), hydrazine (Hyd), branched polyethylenimine (PEI) 
(typical weight average molecular weight, Mw ~ 25 kDa, PDI of 2.5), chloroform (ACS 
grade), sterile-filtered dimethyl sulfoxide (DMSO), methyl tetrazolium (MTT) powder, 
phenol red free Dulbecco's modified Eagle medium (DMEM), ethidium bromide and 
Tris-Acetate-Ethylenediaminetetraacetic acid (EDTA) (TAE) were purchased from 
Sigma-Aldrich (St. Louis, MO). Deuterium oxide (D2O) was obtained from Cambridge 
Isotope Laboratories, Inc. (Andover, MA). Acetone (ACS grade), isopropanol (ACS 
grade) and Fisher Certified Buffer pH 5.0 and 7.4 were purchased from Fisher Scientific 
(Pittsburgh, PA). Fischer rat fibroblast 3T3-like cell line (CRL 1764) was obtained from 
American Type Culture Collection (Manassas, VA). DMEM and phosphate-buffered 
saline (PBS) were purchased from Gibco Life (Grand Island, NY). Fetal bovine serum 
(FBS) was obtained from Gemini Bio-Products (Calabasas, CA). Trypsin-EDTA (0.25% 
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trypsin/0.02% EDTA) was obtained from Invitrogen (Carlsbad, CA). Poly(ethylene 
glycol) (PEG) standards with Mn ranging from 102 to 82,500 Da used for SEC were 
obtained from Waters (Milford, PA). pDNA with a cytomegalovirus (CMV) promoter 
and enhanced green fluorescent protein (eGFP) reporter gene (pCMV-eGFP, 4.7 kb, cat 
no. 6085-1) was obtained from Clontech (Palo Alto, CA). Qiagen Endofree Plasmid Giga 
Kit was purchased from Qiagen (Valencia, CA). 
Polymer Synthesis 
Synthesis at Room Temperature (P-AEPZ) 
P-AEPZ (Table IV-1) was synthesized by reacting AEPZ with TMPTA as 
X7 1 0 7 • &7 QO Q1 
previously described ' . Briefly, the polymer was synthesized at a 2:1 mole ratio ' ' 
of amine to triacrylate monomer in chloroform. The mixture was allowed to react for 8 
days under ambient temperature and then purified by precipitation in a solution of 400 
mL of acetone and 5 mL of hydrochloric acid (HC1) (12 M). The product was washed 
with excess acetone and finally vacuum dried to remove any remaining solvent. The H-
NMR spectra revealed the following characteristic signals: P-AEPZ: 8 0.9 (t, C-CH2-
CH3), 1.4 (m, C-Ci72-CH3), 2.5-3.5 (t, -CH2-C#2-NR2- and t, -CH2-C//2-COO-CH2-), 
4.0-4.1 (s, C-C/6-OOC-CHr-). 
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Table IV-1 Polymer composition and structures of the triacrylate and amine monomer 
building blocks. P-AEPZ, P-API, P-DED, P-Hyd, P-AEPZ/Hyd, and P-API/Hyd vary in 
the type of amines they comprise. 
Group 
P-AEPZ 
P-API 
P-DED 
P-Hyd 
P-AEPZ/Hyd 
P-API/Hyd 
Triacrylate Monomer 
OU 
OL--^ 
TMPTA 
O ^ 
TMPTA 
^Ao-i 
TMPTA 
OU 
TMPTA 
OU 
OL—-. 
TMPTA 
O U OC-^ 
TMPT/O i 
Amine Monomer 
Q 
S 
NH2 
AEPZ 
H,N 
API 
NH2 
AEPZ 
^N. o 
N—" 
API 
NH, 
\ 
DED 
NH2 
/ 
H2N 
Hydrazine 
NH, 
/ 
H2N 
Hydrazine 
NH2 
/ 
H2N 
Hydrazine 
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Synthesis at 50°C (P-API, P-DED, P-Hyd, P-AEPZ/Hyd and P-API/Hyd) 
All other polymers (Table IV-1) were synthesized by reacting TMPTA with API 
(P-API), DED (P-DED), Hyd (P-Hyd), AEPZ and Hyd (1:1 mole ratio) (P-AEPZ/Hyd) 
and API and Hyd (1:1 mole ratio) (P-API/Hyd) on the basis of previous methods90'91. The 
polymers were synthesized at a 2:1 mole ratio of amine to triacrylate monomer. Typically, 
10.8 mmole of the amine monomer and 5.4 mmole of the triacrylate monomer were 
mixed in 20 mL of chloroform in a round bottom flask. For P-AEPZ/Hyd and P-API/Hyd, 
5.4 mmole of each type of amine monomer was used, which resulted in a total of 10.8 
mmole of amine monomer. The mixture was allowed to react for 3 days at 50°C. The 
polymer was then purified by precipitation in a solution of 400 mL of acetone and 5 mL 
of concentrated hydrochloric acid (12 M). The product was washed with excess acetone 
and finally vacuum dried to remove any remaining solvent. The 'H-NMR spectra 
revealed the following characteristic signals: P-DED: 5 0.9 (t, C-CH2-Ctfj), 1.4 (m, C-
CH2-CH3), 2.5-3.7 (t, -CH2-C//2-NR2-, s, -CH3-N- and t, -CH2-Ci/2-COO-CH2-), 
4.0-4.1 (s, C - G F / T - O O C - C H Z - ) . P-Hyd: 5 0.9 (t, C-CH2-C/f5-), 1.4 (m, -C//2-CH3-), 
2.3-3.6 (t, -CH2-C#2-NH-NH- and t, - C H H ^ - C O O - C H r - ) , 4.0-4.1 (s, C-CH2-
OOC-CH2-). P-AEPZ/Hyd: 8 0.9 (t, C-CH2-Gtf5), 1.4 (m, C-C//2-CH3), 2.5-3.6 (m, -
CH2-CH2- NR2, t, -CH2-C//2-NH-NH- and t, -CH2-C//^COO-CH2-), 4.0-4.1 (s, C-
Ci/r-OOC-CH2-). P-API/Hyd: 5 0.9 (t, C-CH2-CH3), 1.4 (m, C-Ci/r-CH3-), 2.1 (m, -
NR2-CH2-C#2-CH2-NR2-), 2.1-3.5 (t, -CH2-C//2-NR2- t, -CH2-Ctf^NH-NH- and t, 
-CH2-C//^COO-CH2-), 4.0-4.1 (s, C-CH2-OOC-CH2-). 4.3 (t, -CH2-C//2-
imidazole-), 7.2-7.4 (d, -N-C#=Ci/-N-), 8.3 (s, -N=CJ7-N-). 
Polymer Characterization 
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The results reported for P-AEPZ in this study (i.e., polymer molecular weight, 
hydrogen ion titration and ester degradability and polymer/pDNA polyplex zeta potential, 
band retardation and hydrodynamic diameter) are adopted from a previous study 
(represented as P-OE/M)107. Experiments that involve cells (i.e., cytotoxicity and 
transfection efficiency studies) were repeated to avoid variations between different cell 
pools. 
Proton Nuclear Magnetic Resonance ^H-NMR) 
'H-NMR spectra of the polymers were obtained using a 400 MHz Bruker 
spectrometer (Bruker Avance 400, Zurich, Switzerland). The samples were dissolved in 
deuterium oxide (D2O) and the resulting spectra were analyzed using MestRe-C, a NMR 
processing software package (Mestrelab Research S. L., Spain). The proton peak of 
deuterium protium oxide (HDO) was used as the internal shift reference and therefore set 
to 5 = 4.8 ppm. 
Molecular Weight Determination by Size Exclusion Chromatography (SEC) 
The weight average molecular weight (Mw), number average molecular weight 
(Mn) and polydispersity index (PDI) (Mw/Mn) of the polymers were determined by SEC 
using a Waters Alliance® HPLC system (Waters, Milford, PA) equipped with a 
differential refractometer as previously described107. Briefly, the samples were run 
through a Shodex OHpak SB-G (6.0 x 50 mm) guard column, a Shodex OHpak SB803 
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HQ (8.0 x 300 mm) and a Shodex OHpak SB802.5 HQ (8.0 x 300 mm) analytical column 
placed in series using PEG standards with Mn ranging from 102 to 82,500 Da to obtain a 
calibration curve (as previously done by Wu et al.87 and our group107 for polymers with 
similar architecture to those synthesized in this study). A 0.5 M sodium acetate buffer 
containing 0.1 M sodium nitrate was used as the mobile phase (pH 4.5) with a flow rate 
of 0.5 mL/min. The theoretical average compositions of the polymers were calculated as 
previously described107. 
Hydrogen Ion Titration 
The number of amine equivalents in a given mass of polymer was evaluated by 
hydrogen ion titration as done previously . Briefly, 50 mg of polymer were dissolved in 
10 mL of 150 mM sodium chloride (NaCl) solution. The polymer solution was adjusted 
to a pH of 2.0 and then titrated by stepwise addition of 0.1 N NaOH while measuring the 
pH of the solution using an accumet* AP63 Portable pH meter (Fisher Scientific, 
Pittsburgh, PA). Each titration was done in triplicate, and average pH values were 
calculated and reported. The amine equivalents that dissociated in different pH ranges 
were determined as previously described107'114. The pKa values were obtained from the 
titration curves as the pH values at 50% ionization or half way to the equivalent point 
(midpoint of the plateau areas on the curves). 
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Polymer Degradation by H-NMR Analysis 
The rate of hydrolytic ester degradation of the polymers was determined at pH 5.0 
and 7.4 by ^-NMR analysis as previously described87'107'115,116. Briefly, a polymer 
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sample (7.5 mg) was dissolved in 750 uL of Fisher Certified Buffer pH 5.0 or pH 7.4 
and incubated at 37°C with constant agitation (75 rpm). At predefined time points (0 h, 6 
h, 12 h, 1 d, 3 d, 7 d and 14 d), the samples were analyzed by ^-NMR. This study was 
done in triplicate (n=3). At each time point, percent ester degradation was calculated as 
previously described107. 
Cytotoxicity Analysis by MTT Assay 
The cytotoxicity of the polymers was evaluated using an MTT viability assay as 
described previously107'118. Briefly, CRL 1764 rat fibroblasts were plated on 96-well 
plates with a density of 8000 cells/well. Polymer solutions with a pH of 7.4 and an 
osmolality of 280-320 mosm/kg were prepared in DMEM at six polymer concentrations 
(10, 50, 100, 250, 500 and 1000 ug/mL). Branched PEI (Mw ~ 25 kDa) solutions at the 
same concentrations were used as negative controls. Branched PEI 25 kDa has been 
widely evaluated and is often used as a control for cytotoxicity studies by other groups in 
the literature87'119. After 24 h of cell attachment, the cells were incubated for 2 and 24 h at 
37°C in the presence of 100 uL of the polymer solution. MTT assay was performed 
immediately after the two time points and the absorbance was measured at 570 ran using 
an absorbance microplate reader (Powerwave X340, BIO-TEK Instruments, Winooski, 
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VT). The average number of live cells was calculated from 5 different samples as 
previously described . 
Polymer/pDNA Polyplex Characterization 
Amplification and Purification of Plasmid DNA 
pCMV-eGFP was amplified in Escherichia coli (E. coli) bacterial cultures and 
purified using a Qiagen Endofree Plasmid Giga Kit according to the protocols provided 
by the manufacturer. The yield of pDNA was determined from the UV absorbance at a 
wavelength of 260 nm (A260) (NanoDrop™ 1000 Spectrophotometer, Thermo Scientific, 
Wilmington, DE). To evaluate plasmid purity, the ratio of the UV absorbance at 
wavelengths of 260 nm and 280 nm (A260/A280) was determined and found to range 
between 1.8 and 2.0. The pCMV-eGFP plasmid was used in all of the polymer/pDNA 
polyplex characterization experiments. 
Zeta Potential 
The zeta potential of polymer/pDNA polyplexes at different polymer to pDNA 
weight ratios (5:1, 10:1, 50:1, 100:1, 200:1 and 300:1) was obtained as previously 
described . Briefly, the polyplexes were prepared with 10 |J,g of pDNA in 600 uL PBS. 
The zeta potential of the resulting particles or larger aggregates was obtained using a Zen 
3600 Zetasizer (Malvern Instruments, Worcestershire, UK) at 25°C. The zeta potential 
was calculated using the Smoluchowski equation based on the electrophoretic mobility 
This study was done in triplicate. 
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Band Retardation with Gel Electrophoresis 
Band retardation of the polyplexes at different weight ratios (10:1, 20:1, 30:1, 
40:1, 60:1, 80:1 and 100:1) of polycationic polymer to pDNA solutions was performed as 
previously described107. Briefly, the polyplexes were prepared from 1 ug pDNA in 20 jaL 
PBS and loaded into the wells of a 0.5% (w/w) agarose gel with bromophenol blue 
loading solution. The gel was run for 1 h at 80 mV in TAE buffer (lx) and an image of 
the gel was captured in a UV transillumination box. 
Hydrodvnamic Polyplex Sizes by Dynamic Light Scattering (DLS) 
The hydrodynamic diameter of the polycationic polymer/pDNA polyplexes was 
evaluated at different polymer to pDNA weight ratios (10:1, 50:1, 100:1, 200:1, 300:1 
and 500:1) using a 90PLUS Particle Size Analyzer (Brookhaven Instruments Corporation, 
1 07 
Holtsville, NY) . In brief, the polyplexes were prepared with 10 ug pDNA in 600 uL of 
PBS and analyzed in the instrument. The diameter of the polyplexes or aggregates thereof 
was obtained using Laplace inverse program Non-Negative Least-Squares (NNLS)119. 
This study was done in triplicate. 
eGFP Transfection of Rat Fibroblasts 
The transfection of CRL 1764 rat fibroblasts was performed as previously 
described107. Rat fibroblasts were plated in 6-well plates at a seeding density of 250,000 
cells/well. After 24 h of cell attachment, the cells were incubated in the presence of 100 
(j,L of polyplex solution containing 5 jag of pDNA complexed at different polymer/pDNA 
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weight ratios (10:1, 50:1, 100:1, and 300:1) and 400 uL of DMEM (FBS free). 
PEI/pDNA at a weight ratio of 2:1, naked pDNA and FBS-free media without pDNA 
served as controls. After 24 h, the cells were supplemented with 2 mL of DMEM/FBS 
(10% (v/v)) which resulted in a solution containing 8% instead of 10% (v/v) of FBS. The 
slightly lower concentration of FBS was not expected to significantly affect the 
metabolism of the cells. After 48 h, the cells were then trypsinized and fixed with chilled 
formaldehyde solution (1%). Samples were then analyzed using a flow cytometer (Becton 
Dickenson FACS Scan, BD Biosciences, San Jose, CA). This study was conducted with 
n=4-6. Fluorescence images of selected samples were taken with a confocal microscope 
(Zeiss LSM 510, Carl Zeiss Jena, Germany) to confirm transfection and expression of the 
green fluorescent protein (GFP). The cells were imaged with a 20x objective after 
excitation by an argon laser. We ensured that the highest weight ratios tested in the 
transfection study had a lower mass of polymer per unit area of culture well (150 |ig/cm , 
weight ratio of 300:1) compared to that tested in the cytotoxicity experiment. In the 
cytotoxicity experiment, cells exposed to the highest mass of polymer per unit area of 
culture well tested, 300 fxg/cm (polymer concentration of 1000 (o,g/mL), were still viable. 
Statistical Methods 
The results were presented as means ± standard deviation. Multiple-factor 
analysis of variance (ANOVA) was used to identify if there were any significant 
differences among groups (p < 0.05). Tukey's Honestly Significantly Difference (HSD) 
test was then conducted to identify the specific groups that differed statistically 
significantly. 
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Results and Discussion 
Polymer Synthesis 
A series of polymers were synthesized and precipitated in acetone/HCl. The 
sticky precipitates were solid, rubbery or a viscous liquid. In their protonated form, the 
polymers were insoluble in organic solvents, thus all characterizations were done in 
aqueous media. An exemplary structure of the synthesized branched polymers is shown 
in Figure IV-1 with DED as the amine monomer. 
Figure IV-1 General structure of a branched polymer obtained by Michael addition 
reaction of TMPTA with an amine monomer (shown here: DED). 
Different synthesis methods (room temperature/non-heated or heated) had to be 
applied to yield the different polymers. P-AEPZ was obtained at ambient temperature. If 
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polymerized at 50°C, the reaction solution of P-AEPZ formed a cross-linked gel. All 
other polymers were synthesized at an elevated temperature (50°C) because reactions at 
room temperature were incomplete, as indicated by the presence of olefmic proton 
signals (5.8-6.6 ppm) in the 'H-NMR spectra of the final products. The synthesis of P-
API was incomplete even when the synthesis was performed at temperatures above 50°C 
or at increased reaction time and amine monomer concentration. Any unreacted acrylate 
groups in P-API could possibly contribute to polymer toxicity121, thus P-API was 
excluded from further characterizations. The synthesis of P-Hyd was complete with 
regard to acrylate group conversion (no olefinic proton peaks present), however, the 
polymeric product only dissolved in acidic solutions. Thus, P-Hyd was only characterized 
by hydrogen ion titration. The yields of the polymerization were between 80-90%. 
The obtained ^-NMR data were also used to verify that the polymer building 
blocks, amine and triacrylate monomer, reacted at the intended molar ratio of 2:1, which 
represents the monomer ratio at initiation. The integral of the signals between 2.5-3.5 
ppm (derived from -CH2-C/6-NR2- (of the amine monomers AEPZ, API, DED), H3C-
NR2- (of DED), -CH2-C/J2-NR2- formed through the reaction, and -C#2-COO-CH2-
from the triacrylate monomer) was compared to the integral of the proton signal at 0.9 
ppm (derived from three methyl protons in the triacrylate monomer). The calculations 
yielded molar ratios for P-AEPZ, P-DED, P-AEPZ/Hyd and P-API/Hyd of 1.8, 2.3, 2.5, 
and 1.7, respectively. 
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Polymer Characterization 
Molecular Weight with Size Exclusion Chromatography 
The Mn, Mw and PDI of the polymers as obtained by SEC as well as the 
theoretical average composition of the polymers calculated based on the experimental Mn 
and Mw values are shown in Table IV-2. P-AEPZ, which on average consists of 4 
triacrylate and 8 amine monomers, had a higher molecular weight (Mn of 2700 Da) 
compared to the other polymers which on average consisted of only 2 triacrylate and 4 
amine monomers (Mn < 1000 Da). 
Table IV-2 Number average molecular weight, weight average molecular weight, 
polydispersity index (PDI), estimated average number of triacrylate and amine monomers 
per polymer molecule and pKa values of the polymers examined in this study. Values for 
P-AEPZ are adopted from a previous study107. 
Number of 
Amine pKa/ pKa2* pKa3# 
Monomers 
8(20) 7.85 
4(4) 5.56 9.56 
4.24 
4 (4) 6.34 9.61 
4(4) 4.14 6.32 8.96 
* Measured by size exclusion chromatography 
Estimated from number average molecular weight; numbers in parentheses estimated 
from weight average molecular weight 
Determined from titration curve 
Polymer 
P-AEPZ 
P-DED 
P-Hyd 
P-AEPZ/Hyd 
P-API/Hyd 
Mn 
(Da)* 
2700 
838 
-
812 
796 
Mw 
(Da)* 
6671 
946 
-
888 
840 
PDI* 
2.47 
1.13 
-
1.09 
1.06 
Number of 
Triacrylate 
Monomers 
4(10) 
2(2) 
-
2(2) 
2(2) 
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Only P-AEPZ was synthesized at room temperature, while all other polymers were 
synthesized at 50°C, which may have contributed to the observed differences in 
molecular weight and monomer composition. Another possible explanation for the 
different degrees of polymerization may be the different reactivity of the amine 
monomers used . Low molecular weights were obtained for the synthesized polymers. 
The molecular weights of the polymers were obtained with SEC using linear PEG 
standards to generate the calibration curve. The calibration with a linear polymer may not 
account for the effect of branching that may be present in the polymers; thus an 
underestimation of the molecular weights may have occurred. The molecular weight97 
and degree of branching of polymers are factors that can highly affect the parameters 
of non-viral gene delivery polymers which in turn can affect their transfection 
efficiencies. 
Determination of Buffering Profiles and Polymer pKa Values by Hydrogen Ion Titration 
Hydrogen ion titration of the polymers was started at pH 2 with sodium hydroxide 
until a pH of 12 was reached, in order to avoid degradation of the polymers at basic pH. 
The obtained titration curves are shown in Figure IV-2. Table IV-2 summarizes the pKa 
values that were determined for the synthesized polymers. The building block AEPZ has 
a primary, secondary and tertiary amine and a specified pKa value of 9.30. API has a 
primary amine with a pKa of 9.81 and a basic imidazole amine with a pKa of 6.28. 
Imidazole polymers have been shown to exhibit buffering capacity in the 
endosomal/lyosomal pH range and are often incorporated into polymers as endosomal 
124 128 1 \L 
escape moieties ' ' . 
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Figure IV-2 Titration curves (0.1 N NaOH) of the polymers. Values for P-AEPZ are 
adopted from a previous study . The results are expressed as means + standard 
deviations for n=3. 
The ethylenediamine group in DED, used previously by Kim et al.90'91, is a diacid 
molecule and forms a 5-membered ring with a gauche-anti conformational transition 
upon protonation , which results in pKa values of 9.74 and 6.36. Xiong et al. have 
synthesized a polymer containing hydrazide moieties, which are characterized by a low 
pKa of around 5.00 and therefore remain predominantly uncharged at physiological pH134. 
Xiong et al. found that polymeric hydrazide moieties do not participate in the proton 
sponge effect due to the low pKa1 . These functionalities, however, may be beneficial 
for poly(ester amine) degradation. Amines with low pKa values, which remain 
199 
unprotonated at pH 5.0 or 7.4, can autocatalyze the degradation of esters at that pH . In 
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this work, we found that the pKa value of hydrazine decreased from 7.97 (monomer) to 
4.24 upon conversion into a higher order amine during polymerization (P-Hyd). 
In general, the pKa values of the amines (Table IV-2) changed upon conversion in 
the Michael addition reaction as a result of the increase in alkyl substitution during the 
reaction. Sterically hindered accessibility also contributes to the observed changes in the 
pKa values of the amines. The molecular weight and degree of branching of the polymers 
could also affect the dissociation of the amines. As seen in Table IV-1, the polymers that 
were synthesized cover a wide range of pKa values as intended by the choice of the 
different amine monomers. P-AEPZ had a single pKa of 7.85. Through the addition of 
amines from amine monomers DED, Hyd and API, polymers were produced that 
contained amine groups with pKa values above and below 7. The incorporation of the 
amine monomer DED resulted in a polymer (P-DED) with two pKa values, 9.56 for the 
primary amine of the monomer, which could have become secondary or tertiary upon 
polymerization, and 5.56 for the tertiary amine that dissociates through the gauche-anti 
conformational transition. The incorporation of the amine monomer API in P-API/Hyd 
resulted in a pKa of 8.96 for the primary amine of the monomer, which could have 
become secondary or tertiary upon polymerization, and an additional, low pKa value of 
6.32 for the imidazole amine. The amine monomer Hyd which was incorporated into P-
Hyd, P-AEPZ/Hyd and P-API/Hyd, resulted in an additional low pKa value of 4.24, 6.34 
and 4.14, respectively. By incorporating two different amine monomers in the polymer, 
such as in P-AEPZ/Hyd and P-API/Hyd, the resulting polymers displayed multiple pKa 
values covering a wide pH range. 
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The titration curves for the four synthesized polymers were all different in shape 
(Fig. IV-2), which demonstrates that the type of amine monomer had a significant effect 
on the buffering capacity and profile of the polymers. In contrast, polymers made from 
the same type of amine monomer (AEPZ), were very similar in shape107. 
The amine equivalents dissociating in four different pH ranges were evaluated for 
a given mass of polymer (typically: 50 mg) as done in previous work107 (Fig. IV-3). 
P-AEPZ • P-DED Q P-AEPZ/Hyd P-API/Hyd 
pH 2.5-5.0 pH 2.5-7.4 pH 5.0-7.4 pH 7.4-11.0 
pH Range 
Figure IV-3 Amine equivalents that dissociate within different pH ranges. The results 
represent means ± standard deviations for n=3. # indicates a statistically significant 
difference between one polymer and all other polymers within the same pH interval 
(p<0.05). Values for P-AEPZ are adopted from a previous study107. * represents a 
statistically significant difference between two polymers within the same pH interval 
(p<0.05). 
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The amine equivalents that dissociate between pH 2.5 - 5.0 and pH 2.5 - 7.4 were 
evaluated in order to compare the availability of unprotonated amines, which may 
catalyze the degradation at pH 5.0 and 7.4, respectively122. The amine equivalents that 
dissociate at pH 5.0 - 7.4 were obtained to evaluate the buffering capacity of the 
polymers at the endosomal/lysosomal pH range, which determines the polymer's ability 
to aid in pDNA escape from the endosome prior to lysosomal degradation by nucleases . 
The amine equivalents dissociating between pH 7.4 - 11.0 are charged at physiological 
pH and considered to aid in polymer/pDNA polyplex formation at pH 7.4. 
For a given mass of polymer (50 mg), P-AEPZ had the highest buffering capacity 
in the range relevant to assist in endosomal escape (pH 5.0-7.4) as compared to the other 
polymers (Fig. IV-3). Compared to P-AEPZ, the other polymers (P-DED, P-AEPZ/Hyd 
and P-API/Hyd) had significantly more amines dissociating in the pH range of 2.5 to 5.0. 
Such amine groups can help catalyze polymer degradation at pH 5.0. P-AEPZ and P-
API/Hyd had the highest amount of amines that may assist with the catalysis of 
hydrolytic degradation at pH 7.4 compared to the other polymers. Compared to all other 
polymers, P-DED had a significantly higher number of amines dissociating between pH 
7.4 and 11.0; dissociation above pH 7.4 is important for polyplex assembly at this pH. 
The high pKa values of P-DED and P-AEPZ/Hyd were similar (9.56 and 9.61, 
respectively), however, the buffering profiles of the polymers at pH 7.4 (cytoplasmal pH) 
are significantly different. This demonstrates that it is not only important to compare the 
pKa values of the polymers, but also the buffering profiles and amount of amine 
equivalents at the different pH ranges. The data in Figure IV-3 also illustrates that the 
polymers synthesized from various amine monomers, which resulted in different 
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molecular weights and molar contents of amine groups, significantly varied in the amine 
equivalents dissociating in the four investigated pH ranges. When the triacrylate 
monomer chemistry was varied, as done in our previous work, the amount of amine 
equivalents dissociating in the four investigated pH ranges decreased as the hydrophilic 
spacer length increased and did not vary significantly between the different pH ranges . 
Polymer Degradation with 'H-NMR Analysis 
The degradation profiles of the polymers at pH 5.0 and 7.4 are shown in Figure 
IV-4A and IV-4B, respectively. Figure IV-4C compares the polymers at two time points 
(3 and 14 days). Even though P-DED, P-AEPZ/Hyd and P-API/Hyd had more 
unprotonated amines at pH 5.0 (Fig. IV-3), their rates of degradation at day 3 were still 
significantly lower than those observed for P-AEPZ at pH 5.0 (Fig. IV-4C). P-DED, P-
AEPZ/Hyd and P-API/Hyd may have formed polymers with structures in which the 
polymer chains are not as flexible, thus, the unprotonated amines in the polymers are less 
likely to interact with the ester groups and catalyze the degradation of the polymers. 
Furthermore, P-AEPZ may have formed a polymer with more accessible ester groups. P-
DED, P-AEPZ/Hyd and P-API/Hyd may have more hidden ester groups, which can result 
in the reduction in the rate of hydrolysis135. The results from this study suggest that 
although a polymer has a higher amount of amines that may autocatalyze degradation, 
other factors, such as accessibility of the ester groups and flexibility of the polymer 
chains to allow for the interaction of the unprotonated amines and ester groups, may also 
affect hydrolysis and result in a lower degradation rate. 
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Figure IV-4 Ester degradation profiles of the polymers at 37°C and (A) pH 5.0 
simulating lysosomal pH and (B) pH 7.4 simulating cytoplasmic pH and (C) degree of 
degradation after 3 and 14 days at pH 5.0 and 7.4 at 37°C as observed by 'H-NMR. The 
extent of degradation is expressed as means ± standard deviation for n=3. # indicates a 
statistically significant difference between one polymer and all other polymers degraded 
under the same conditions (p<0.05). Values for P-AEPZ are adopted from a previous 
study107. * represents a statistically significant difference between two polymer 
compositions degraded under the same conditions (p<0.05). 
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Further studies that investigate the polymer architecture and topology will give a better 
understanding regarding the differences in degradation rates seen in this study. P-
AEPZ/Hyd achieved around the same amount of degradation as P-AEPZ by day 14 
(-45% and 90% at pH 5.0 and 7.4, respectively). -80% of the esters in P-AEPZ degraded 
after 3 days and -80%) of the esters in P-DED degraded after 14 days at pH 7.4. These 
two polymers will be good candidates for evaluating pDNA release kinetics from 
polycationic polymers with a high (P-AEPZ) and low (P-DED) degradation rate. A 
higher rate of degradation was seen for all the polymers at pH 7.4 (cytoplasmal pH) than 
at pH 5.0 (lysosomal pH). This resulted from the higher number of unprotonated amine 
groups that are present at the higher pH to catalyze hydrolysis of the ester groups, which 
is consistent with previous work on poly(ester amine)s ' ' . 
Cytotoxicity Analysis 
Cells remained viable after incubation with the synthesized polymer solutions for 
2 and 24 h at all tested concentrations. More than 85% of the cells exposed to the 
synthesized polymers were viable at all concentrations (Fig. IV-5). In contrast, PEI 
caused significant cell death after 2 h with less than 12% cell viability at a concentration 
of 250 ng/mL and higher and after 24 h with less than 6% cell viability at a concentration 
of 10 (ig/mL and higher. PEI (25 kDa) has a molecular weight which is 9 times higher 
than that of P-AEPZ and around 30 times higher than that of all other polymers. 
Furthermore, PEI has a charge density which is approximately 2 times higher compared 
to the polymers synthesized in this study. The high toxicity of PEI may have resulted 
1 93 194 
from these two parameters ' . 
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Figure IV-5 Cytotoxicity of the polymers with polyethylenimine (PEI; 25kDa) as 
negative control) on CRL 1764 rat fibroblasts after (A) 2 h and (B) 24 h as evaluated by 
an MTT assay. The results are expressed as means ± standard deviation for n=5. 
The improved cytocompatibility of the developed polycationic polymers will allow for 
the use of these polymers at high concentrations and high N:P ratios. Especially P-DED, 
which contains a considerable amount of amines that dissociate at and above pH 7.4 and 
is therefore strongly charged at this pH, and showed good cytocompatibility even when 
exposed to cells at concentrations as high as 1000 jag/mL. 
87 
Polymer/pDNA Polyplex Characterization 
Zeta Potential 
The optimal polymer to pDNA ratios are those which result in a polyplex with a 
positive surface charge that allows the polyplex to interact with the negative charges on 
the cell membrane ' . The pCMV-eGFP plasmid, which was used in this study, has a 
zeta potential of -33.1 ± 0.5 mV. All the polyplexes formed at a polymer/pDNA weight 
ratio of 5:1 had a negative zeta potential ranging between -8.5 and -30.0 mV (Fig. IV-6). 
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Figure IV-6 Zeta potential of the polyplexes formed with 10 \xg pCMV-eGFP DNA at 
different polymer/pDNA weight ratios. The results are expressed as means ± standard 
deviation for n = 3. # indicates statistically significant difference between a polyplex and 
all other polyplexes formed at the same weight ratio (p<0.05). Values for P-AEPZ are 
adopted from a previous study107. * represents a statistically significant difference 
between two polyplexes formed at the same weight ratio (p<0.05). 
88 
At a weight ratio of 10:1, P-AEPZ and P-DED formed polyplexes characterized by a zeta 
potential of 0.0 ± 0.0 mV and 13.9 ± 0.5 mV, respectively. P-AEPZ/Hyd and P-API/Hyd, 
which contain a lower number of amines per weight of polymer that are protonated at pH 
7.4 and that can participate in pDNA complexation as compared to P-AEPZ and P-DED 
(Fig. IV-3), formed negative polyplexes at a weight ratio of 10:1 and positive polyplexes 
at a weight ratio of 50:1. Half of the amine monomers in P-AEPZ/Hyd (synthesized from 
a 1:1:1 mole ratio of TMPTA:AEPZ:Hyd) and P-API/Hyd (synthesized from a 1:1:1 
mole ratio of TMPTA:API:Hyd) are derived from hydrazine, which is characterized by a 
low pKa once incorporated into the polymers. Thus, the amines will not be protonated at 
physiological pH (7.4) and therefore cannot contribute to the complexation of pDNA. As 
a result, a higher polymer to pDNA ratio is needed for P-AEPZ/Hyd and P-API/Hyd to 
neutralize the charges of the pDNA as compared to P-AEPZ and P-DED. Polyplexes 
formed with P-DED generally showed higher zeta potentials as compared to all other 
polymers due to the polymer's high buffering capacity above pH 7.4, which results in a 
higher number of protonated amines at pH 7.4 that are available for pDNA complexation 
(Fig. IV-3). The zeta potential of all polyplexes formed by the synthesized polymers 
increased as the weight ratio of polymer to pDNA increased, which corresponds with the 
increased N:P ratios within the polyplexes. 
Band Retardation with Gel Electrophoresis 
The electrophoretic patterns of the polymer/pDNA polyplexes were obtained by 
gel electrophoresis (Fig. IV-7). Lane 8 in all images represents uncomplexed negatively 
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charged pDNA (naked pDNA), which migrated to the positive end of the gels. P-AEPZ 
and P-DED were able to retard the migration of pDNA at polymer/pDNA weight ratios of 
10:1 or higher. P-AEPZ and P-DED neutralized the charges of pDNA at a ratio of 10:1, 
which is in accordance with the results for the zeta potential measurements (Fig. IV-6). 
P-AEPZ 
am ** 
P-AEPZ/Hyd _ P-API/Hyd 
Figure IV-7 Gel retardation assay of pDNA/polymer polyplexes at different 
polymer/pDNA weight ratios: (1) 100:1, (2) 80:1, (3) 60:1, (4) 40:1, (5) 30:1, (6) 20:1, (7) 
10:1, and (8) naked pDNA. Results for P-AEPZ are adopted from a previous study . 
Polyplexes with P-AEPZ/Hyd and P-API/Hyd, which exhibit lower N:P ratios at a given 
polymer/pDNA weight ratio, were able to retard the migration of the pDNA at weight 
ratios of 30:1 or higher and 20:1 or higher, respectively. This is also consistent with the 
zeta potential data (Fig. IV-6). Polymers with a higher amount of protonated amine at pH 
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7.4 (i.e., P-AEPZ and P-DED) were able to retard the migration of pDNA at a lower 
polymer/pDNA weight ratio. 
Hydrodynamic Size with Dynamic Light Scattering (DLS) 
The hydrodynamic size (diameter) of the polyplexes formed at different 
polymer/pDNA ratios were obtained by DLS (Fig. IV-8). Naked pDNA had a diameter of 
751.6 ± 111.8 nm (data not shown). 
• P-AEPZ • P-DED IZP-AEPZ/Hyd • P-API/Hyd 
2000 - # 
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Polymer/pDNA Weight Ratio 
Figure IV-8 Diameter of the polyplexes formed with 10 jag pCMV-eGFP DNA at 
different polymer/pDNA weight ratios as evaluated by DLS. The results are expressed as 
means ± standard deviation for n=3. # indicates statistically significant difference 
between a polyplex formulation and polyplexes formed by all other polymers of the same 
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weight ratio (p<0.05). Values for P-AEPZ are adopted from a previous study . * 
represents a statistically significant difference between polyplexes of the same weight 
ratio (p<0.05). 
91 
Upon complexation, the polymer and pDNA yielded condensed particles with a diameter 
as small as 111.1 ± 19.9 nm (P-DED, polymer/pDNA weight ratio of 500:1). At low 
polymer/pDNA weight ratios (10:1, 50:1 and 100:1), aggregation of the polyplexes may 
have occurred as indicated by the large particle diameters ranging from 832.0 ± 85.4 nm 
to 1910.5 ± 17.2 nm. At low weight ratios, neutrality of the polyplexes may cause particle 
aggregation as electrostatic repulsion is minimal. The zeta potentials increased as the 
polymer/pDNA ratios were increased (Fig. IV-6) and individual polyplexes were 
electrostatically stabilized54. The large particle diameters observed for polyplexes formed 
with a low polymer/pDNA weight ratio could also have resulted from the inability of the 
polymers to condense pDNA at low polymer/pDNA weight ratios. Polyplexes formed at 
a polymer/pDNA weight ratio of 300:1 or higher were significantly smaller in size 
compared to those formed at a polymer/pDNA weight ratio of 100:1 or lower. Compared 
to the other polymers, P-DED formed individual particles with small particle diameters 
even at the lowest polymer/pDNA ratio tested (10:1). Due to the polymer's high 
buffering capacity above pH 7.4, the formed polyplexes were positively charged even at 
low weight ratios and were able to repulse each other and avoid aggregation. All 
synthesized polymers were able to form complexes with and condense pDNA at 
appropriate N:P ratios, which is beneficial for DNA stabilization and transfection73. The 
polyplexes formed by the synthesized polymers may not be as small as those formed by 
branched PEI (25 kDa), however, they are still promising for gene delivery. Larger sized 
particles have been shown to sediment onto cells, which enhances particle uptake by 
increasing the interaction with the cells in 2D cultures57'126. Although P-AEPZ/Hyd and 
P-API/Hyd form complexes with lower zeta potential compared to P-AEPZ and P-DED 
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(Fig. IV-6), P-AEPZ/Hyd and P-API/Hyd were able to condense pDNA to low 
hydrodynamic sizes at high polymer/pDNA weight ratios. There was no increase in 
surface charge of the polyplexes formed after a certain weight ratio as also observed by 
other groups in the literature87. However, improvement in the condensation of the pDNA 
was still observed. This suggests that above a certain polymer/pDNA weight ratio, 
additional polymer may not increase the surface charge of the polyplexes but it may still 
improve pDNA condensation. 
Transfection Efficiency with Enhanced Green Fluorescent Protein Reporter Gene 
The transfection efficiencies of the polyplexes formed by the synthesized 
polymers were evaluated using rat fibroblasts as a model cell line and the results are 
summarized in Figure IV-9. At low polymer/pDNA weight ratios (10:1, 50:1 and 100:1), 
the polyplexes formed by the synthesized polymers did not result in significantly higher 
numbers of transfected cells as compared to naked pDNA. We hypothesized that this 
resulted from the significantly larger hydrodynamic size of polyplexes formed at the 
lower polymer/pDNA weight ratios compared to at the higher weight ratios (300:1 and 
500:1). The insufficient condensation and stabilization of the pDNA may have led to the 
lower transfection efficiencies observed73. At a polymer/pDNA weight ratio of 300:1, 
polyplexes formed with P-AEPZ, P-DED and P-AEPZ/Hyd resulted in significantly 
higher transfection efficiencies (11.8 ± 2.6%, 30.6 ± 6.6% and 5.3 ± 1.0%, respectively) 
than naked pDNA (0.8 ± 0.4%). 
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Figure IV-9 Efficiency of CRL 1764 cell transfection with polyplexes formed with 5 jixg 
pCMV-eGFP DNA at different polymer/pDNA weight ratios. Naked pDNA and 
polyplexes formed by PEI at a polymer/pDNA weight ratio of 2:1 served as controls. The 
results are expressed as means ± standard deviation for n = 4-6. * indicates a statistically 
significant difference between a polyplex and naked pDNA (p<0.05). # indicates a 
statistically significant increased transfection efficacy as compared to the transfection 
efficacy of PEI/pDNA polyplexes (p<0.05). 
At this weight ratio (300:1), polyplexes formed with P-DED, which has the highest 
number of dissociated amines available for pDNA complexation (Fig. IV-3), even 
resulted in a significantly higher transfection efficiency (30.6 ± 6.6%) than observed for 
polyplexes formed with PEI (weight ratio of 2:1, 25.5 ± 2.7%). Compared to all other 
synthesized polymers, P-DED had the highest amount of amines that dissociate above pH 
7.4 which are available for pDNA complexation. P-DED showed more efficient pDNA 
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complexation and condensation and formed polyplexes with higher zeta potential (Fig. 
IV-6). This is especially beneficial for effective interaction with negatively charged cell 
membranes and cellular uptake. The high transfection efficiencies observed are a good 
indication that the polyplexes were successfully internalized by the cells and led to 
expression of GFP. As compared to PEI, a much larger excess of P-DED was required for 
effective pDNA complexation and cellular transfection, which is explained by the 
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comparatively low molecular weight and low charge density of P-DED ' . Due to the 
excellent cytocompatibility of P-DED (Fig. IV-5), such high polymer to pDNA ratios are 
not a concern. 
Fluorescence images were taken to confirm the transfection results obtained by 
flow cytometry. A fluorescence image of cells treated with plain media was taken as a 
negative control (Fig. IV-10A). There was no transfection observed for cells exposed to 
media containing naked pDNA (Fig. IV-10B). Cells exposed to polyplexes formed with 
P-DED at a weight ratio of 300:1 had intense expression of GFP as seen by the bright 
green fluorescence in Figure IV-10C. Cells that were transfected with polyplexes formed 
with PEI (at a weight ratio of 2:1) also showed significant expression of GFP (Fig. IV-
10D), however the fluorescence was not as bright and consistent as observed for 
transfection with P-DED (Fig. IV-IOC). 
Quantitative cytotoxicity evaluation was performed with an MTT assay 2 and 24 
h after incubating the cells with the polymers at different concentrations. Although 
quantitative cytotoxicity evaluation was not performed beyond 24 h after cell treatment 
with the polymer/pDNA polyplexes, qualitative cytotoxicity evaluation was performed 
with light microscopy at the end of the transfection experiment. 
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Figure IV-10 Representative fluorescence images of CRL 1764 cells after exposure to 
the following media: (A) plain medium, (B) naked pDNA (CMV-eGFP), (C) P-
DED/pDNA (300:1), and (D) PEI/pDNA (2:1). In groups B-D, 5 ug pCMV-eGFP DNA 
were used. 
In general, wells treated with polyplexes formed by the synthesized polymers, even at the 
highest polymer/pDNA weight ratio of 300:1, had a high number of live, well spread 
cells (data not shown). In contrast, a very low number of live cells was observed in wells 
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exposed to polyplexes formed with PEL The cytotoxicity observed for PEI has been 
previously reported and likely resulted from the high MW and charge density of the 
polymer . Transfection was performed in the absence of serum in this study. However, 
transfection efficiency can be different with the absence or presence of serum. Future 
transfection studies in vivo in an appropriate animal model will yield a more 
comprehensive analysis of the transfection capabilities of these polymers. 
Conclusions 
In this work polycationic polymers were synthesized from the triacrylate 
monomer TMPTA and different amine monomers by Michael addition polymerization. 
The hypothesis was confirmed that through variations of the amine monomers used in the 
reaction, the amine group density within the polymers and the basicity and buffering 
capacity of the polymers can be controlled. Parameters that are important in the gene 
delivery process were significantly influenced by these properties. It was found that 
amines that dissociate above pH 7.4 and are available for pDNA complexation, are a key 
parameter for effective pDNA condensation and transfection. P-DED, the polymer with 
the most amines dissociating above physiological pH, formed dense polyplexes of high 
zeta potential which transfected cells more efficiently than branched PEI under the 
conditions tested. The evaluation of the synthesized polycationic polymers further 
showed that the availability of unprotonated amines that can autocatalyze degradation 
does not exclusively predetermine the polymer degradation rate. All synthesized 
polymers had low cytotoxicity, which allows their use at high N:P ratios as necessary for 
the fabrication of poplyplexes with effective pDNA complexation and cellular 
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transfection. It is concluded that when designing non-viral vectors, it is important to 
investigate the amount of amines that dissociate in specific pH ranges relevant for 
autocatalytic degradation, pDNA complexation and endosomal escape instead of only 
examining the total amount of amines in the polymer. 
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CHAPTER V 
DELIVERY OF PLASMID DNA ENCODING BONE MORPHOGENETIC PROTEIN-2 
COMPLEXED WITH A BIODEGRADABLE BRANCHED POLYCATIONIC POLYMER FROM A 
COMPOSITE SCAFFOLD* 
Abstract 
This study investigated the delivery of plasmid DNA (pDNA) encoding bone 
morphogenetic protein-2 in the form of polyplexes with a biodegradable branched 
triacrylate/amine polycationic polymer (TAPP), which were complexed with gelatin 
microparticles (GMPs) loaded within a porous tissue engineering scaffold. More 
specifically, the study investigated the interplay between TAPP degradation, gelatin 
degradation, pDNA release and bone formation in a critical-size rat cranial defect model. 
The pDNA release kinetics in vitro were not affected by the crosslinking density of the 
GMPs but depended, rather, on the degradation rates of the TAPPs. Besides the initial 
release of polyplexes not bound to the GMPs and the minimal release of polyplexes 
through diffusion or dissociation from the GMPs, the pDNA was likely released as naked 
pDNA or as part of an incomplete polyplex, following the degradation of fragments of 
the polycationic polymer. After 30 days, significantly higher amounts of pDNA were 
released (93-98%) from composite scaffolds containing naked pDNA or pDNA 
complexed with P-AEPZ (a faster degrading TAPP) compared to those containing pDNA 
+This chapter will be submitted for publication as follows: S.A. Chew, J.D. Kretlow, P.P. Spicer, A.W. 
Edwards, L.S. Baggett, Y. Tabata, F.K. Kasper, and A.G. Mikos, Delivery of Plasmid DNA Encoding Bone 
Morphogenetic Protein-2 with a Biodegradable Branched Polycationic Polymer in a Critical-Size Rat 
Cranial Defect Model (2010). 
99 
complexed with P-DED (a slower degrading TAPP) (74-82%). Composite scaffolds 
containing GMPs complexed with TAPP/pDNA polyplexes did not result in enhanced 
bone formation, as analyzed by microcomputed tomography and histology, in a critical-
size rat cranial defect at 12 weeks post-implantation compared to those loaded with naked 
pDNA. The results demonstrate that polycationic polymers with a slow degradation rate 
can prolong the release of pDNA from the composite scaffolds and suggest that a gene 
delivery system comprising biodegradable polycationic polymers should be designed to 
release the pDNA in an intact polyplex form. 
Introduction 
Bone defects can occur due to trauma, cancer, congenital abnormalities or age-
related degeneration11"14. Defects that have large amounts of bone loss or insufficient 
vascularity are not conducive to bone regeneration and aid may be needed in healing 
these types of defects . Thus, the search for a promising approach to repair these bone 
defects is very much needed. Bone tissue engineering systems delivering bioactive 
factors, that have the capability of inducing bone formation, such as bone morphogenetic 
proteins (BMPs), have been investigated by many groups. BMPs can stimulate 
angiogenesis , promote proliferation of mesenchymal stem cells (MSCs) " , initiate the 
recruitment of osteoprogenitors and MSCs toward the defect site and stimulate the 
differentiation of the cells along an osteoblastic lineage . Delivering the gene encoding a 
BMP is an alternative approach to delivering the BMP in the protein form. Gene delivery 
allows for a longer bioavailability of the protein46, and the resulting protein will have a 
more precise post-translational modification and tertiary structure formation as it is 
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produced in vz'vo136'137. Furthermore, the production of the gene is lower in cost and easier 
compared to the production of the protein. 
When developing a successful gene delivery system, the gene delivery vector is 
not the only important factor that has to be taken into consideration. The carrier that 
delivers the vector/DNA complexes (i.e., scaffold or composite scaffold) also plays a 
critical part in the gene delivery approach. In an ideal non-viral gene delivery system, the 
gene delivery vector has to be capable of condensing and protecting the DNA, facilitating 
delivery of the DNA into the cells and assisting in endosomal escape in order that the 
DNA can be transcribed and translated in the nucleus. Furthermore, the scaffold or 
composite scaffold has to be able to deliver the vector/DNA complexes to or near the 
defect site, control the release kinetics of the complexes and preferably protect the vector 
from degrading before the complexes are delivered into the cells. 
Previous work in our laboratory has investigated the use of composite scaffolds 
comprising gelatin microparticles (GMPs) and porous poly(propylene fumarate) (PPF) to 
deliver BMP-2 for bone tissue engineering18'138. In this work, we investigated the delivery 
of plasmid DNA (pDNA) encoding BMP-2 complexed with a hydrolytically degradable 
polycationic polymer using a similar composite scaffold. The biodegradable branched 
triacrylate/amine polycationic polymers (TAPPs) used in this work have been extensively 
characterized previously in our laboratory108. Polymer/pDNA polyplexes formed with 
these polymers at certain weight ratios have been shown to result in higher transfection 
compared to naked pDNA108. Acidic GMPs, which are negatively charged at 
physiological pH were loaded electrostatically with net positively charged TAPP/pDNA 
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polyplexes. These enzymatically degradable GMPs have been used previously to deliver 
both growth factors18'138'139 and pDNA106'140'141 in a sustained manner. 
The overall objective of this study was to evaluate the ability of composite 
scaffolds comprising pDNA complexed with a TAPP, GMPs and a porous PPF scaffold 
to control the release of pDNA and induce bone formation in a critical-size rat cranial 
defect. We hypothesized that the release of pDNA from these composite scaffolds can be 
controlled by the degradation rates of the TAPPs and GMPs. To test this hypothesis, 
composite scaffolds were fabricated with two different types of TAPPs (P-AEPZ or P-
DED, synthesized with amine monomer l-(2-aminoethyl)piperazine (AEPZ) or N,N-
dimethylethylenediamine (DED), respectively) and GMPs (crosslinked with 10 mM or 40 
mM glutaraldehyde and termed "10 mM" and "40 mM", respectively). The effects of the 
degradation rates of the TAPPs and GMPs on the release kinetics of the pDNA in vitro 
were evaluated. Furthermore, we also hypothesized that the delivery of pDNA complexed 
with a TAPP from the composite scaffolds will result in higher BMP-2 protein expression 
as reflected by greater bone formation compared to the delivery of naked pDNA from the 
composite scaffolds. To test this hypothesis, composite scaffolds were implanted into a 
critical-size rat cranial defect and the capability of these composite scaffolds to induce 
bone formation was evaluated at 12 weeks post-implantation. 
Materials and Methods 
Experimental Design 
All the groups containing pDNA in this study were loaded with the same dose of 
pDNA (160 \xg), which was derived from the dose of pDNA used for the critical-size rat 
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cranial defect study performed by Huang et al. . Based on previous studies in our 
laboratory108, we chose to investigate two different types of TAPPs (P-AEPZ and P-DED) 
that have different degradation rates and transfection efficiencies. At pH 7.4, -80% of the 
esters in P-AEPZ and P-DED degrade after 3 and 14 days, respectively. Polyplexes 
formed with P-AEPZ and P-DED (polymer/pDNA weight ratio of 300:1) result in 11.8 ± 
2.6% and 30.6 ± 6.6% transfection in rat fibroblasts with an enhanced green fluorescent 
protein (eGFP) reporter gene, respectively. Two different types of acidic GMPs (10 mM 
and 40 mM), which vary in the amount of glutaraldehyde used for crosslinking the GMPs 
during fabrication, were investigated. 10 mM acidic GMPs loaded with BMP-2 are 
completely degraded after 9 days in PBS containing collagenase, whereas 40 mM acidic 
GMPs do not show visible degradation after 28 days142. The difference in crosslinking 
density and enzymatic degradation rates of the GMPs has been shown to result in 
different drug release kinetics139'142. Porous PPF scaffolds, which have been used 
previously with GMPs in our laboratory to deliver growth factors18'138, were used as the 
carrier for the GMPs and polyplexes in this study. PPF scaffolds can undergo bulk 
degradation by ester hydrolysis143, and the high porosity of the scaffolds allows for 
circulation of nutrients and metabolic wastes as well as tissue ingrowth, which facilitates 
vascularization and a firm attachment to surrounding tissue144'145. The resulting groups 
for the studies are summarized in Table V-l. 
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Table V-l Composition of pDNA, triacrylate/amine polycationic polymer and gelatin 
microparticles in each group 
Group 
BlanklO* 
Blank_40* 
FreelO 
Free_40 
P-AEPZ10 
P-AEPZ40 
P-DED10 
P-DED40 
Amount of pDNA (jig) 
-
-
160 
160 
160 
160 
160 
160 
TypeofTAPP 
-
-
-
-
P-AEPZ 
P-AEPZ 
P-DED 
P-DED 
TypeofGMP 
10 mM 
40 mM 
10 mM 
40 mM 
10 mM 
40 mM 
10 mM 
40 mM 
*groups included in the in vivo bone formation study but not in the in vitro release 
kinetics study 
Materials 
Pluronic F-127 and bacterial collagenase type 1A were purchased from Sigma-
Aldrich (St. Louis, MO). pDNA with a cytomegalovirus (CMV) promoter and human 
BMP-2 gene (pCMV-hBMP-2, 5.5 kb) was obtained from Invitrogen (Carlsbad, CA). 
PicoGreen Quantification Reagent assay kit was purchased from Molecular Probes 
(Eugene, OR). Fischer-344 rats were purchased from Harlan (Indianapolis, IN). 
PPF Scaffold Preparation and Characterization 
PPF was synthesized as previously described146, and the resulting polymer had a 
number average molecular weight of 2270 and a polydispersity index of 1.53. Porous 
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PPF scaffolds were fabricated as previously reported18'138, and disc-shaped scaffolds (8 
mm diameter x 1 mm thickness) were obtained. Mercury porosimetry (Autoscan 500, 
Quantachrome Instruments, Boynton Beach, FL) was used to evaluate the porosity of the 
scaffolds, as performed previously144. Microcomputed tomography (microCT) was also 
used to analyze the porosity of the scaffolds as previously described138'144, with a global 
binarization threshold of 60-255. The interconnectivity of the scaffolds, which is defined 
as the fraction of the pore volume in the scaffold that is accessible from the outside 
through openings of a certain minimum size147, was also obtained with microCT 
according to established methods ' . The porosity and interconnectivity analyses were 
conducted in triplicate. 
Composite Scaffold Fabrication 
pCMV-hBMP-2 was amplified in Escherichia coli bacteria as done 
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previously1"'' . P-AEPZ and P-DED were synthesized by reacting trimethylolpropane 
triacrylate (TMPTA) with AEPZ and DED, respectively, as previously described108. 
Gelatin with an isoelectric point of 5.0 was used to prepare acidic GMPs using a 
previously established method148, and particles ranging from 50-100 um in diameter were 
obtained. The composite scaffolds were prepared using an adaptation of previous 
methods for loading with growth factors ' . First, a 300 uL solution of polymer/pDNA 
polyplexes containing 160 ug of pDNA were prepared according to established 
1 07 1 08 
methods 1" ' ' . The solutions were then lyophilized to remove the liquid. Preliminary 
studies in our laboratory have shown that there is no significant difference in the 
transfection efficiency for polyplexes formed with and without lyophilization (data not 
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shown). Dry GMPs were then loaded with the lyophilized polyplexes and naked pDNA 
that were resuspended in 25 jn.1 of PBS. For composite scaffolds from groups without 
pDNA (i.e., BlanklO and Blank_40), the dry GMPs were swelled with 25 \i\ of PBS 
alone. Each solution was added drop-wise to 5 mg of GMPs, and the mixture was 
vortexed and left overnight for 20 hours at 4°C. The loaded GMPs were then mixed with 
30 u.L of 24% (w/v) aqueous solution of Pluronic F-127 and injected into the pores of a 
PPF scaffold. 
In Vitro Plasmid DNA Release Kinetics 
Composite scaffolds were prepared as stated above and placed in 1 mL of PBS 
containing bacterial collagenase type 1A at a physiologically relevant concentration (400 
ng/mL) to allow for the enzymatic degradation of the GMPs . The samples were placed 
on an orbital shaker (70 rpm) in a 37°C warm room throughout the duration of the study. 
At each time point (0.5, 1, 2, 3, 7, 10, 17, 24 and 30 d), the release solutions were 
collected and completely replaced with 1 mL of fresh PBS containing collagenase. The 
release samples from each time point were analyzed with a PicoGreen Quantification 
Reagent assay according to the manufacturer's guidelines. 100 \\L of 1 x TE buffer, 50 
\iL of the release solution and 150 uL of a 200-fold dilution of the PicoGreen reagent 
were added to individual wells of an opaque 96-well plate. The fluorescence intensity of 
each well was measured in a fluorescent microplate reader (FLx800, BIOTEK 
Instruments, Winooski, VT) equipped with 480/525 (excitation/emission) filter sets. 
Preliminary studies in our laboratory have shown that the PicoGreen reagent cannot fully 
bind to pDNA that is in a polyplex, as also reported by Kim et al.150. The assay does not 
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allow us to accurately differentiate between and measure the amount of pDNA with 
different extents of complexation (i.e., fully complexed, partially complexed and 
uncomplexed pDNA) at each time point. Thus, after each time point, the collected release 
solutions were further incubated at 37°C for an additional 14 days to allow the TAPPs to 
degrade and release the pDNA from the polyplexes. The PicoGreen Quantification assay 
was then performed on the solutions to quantify the total amount of pDNA released at 
each time point which would include uncomplexed or previously complexed pDNA. 
Standard solutions of known pDNA concentrations ranging from 0-6 ug/mL were used to 
form the calibration curves. The cumulative release at each timepoint was calculated 
using the equation below. This study was conducted at n=4. 
V pDNA released up to time X 
% Cumulative release at time X = — 
pDNA loaded 
In Vivo Bone Formation 
Animal Surgery, Euthanasia and Implant Retrieval 
This study was conducted in accordance with an animal protocol approved by the 
Rice University Institutional Animal Care and Use Committee (IACUC). The composite 
scaffolds were compiled using aseptic techniques and implanted into 11-12 week old 
male syngeneic Fischer-344 rats weighing approximately 250-274 g. The general 
inhalational anesthesia, creation of an 8 mm diameter critical-size cranial defect with a 
trephine drill, placement of composite scaffolds in the defect site and postoperative 
animal care were performed as previously described . 
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The 32 animals from the 4 control groups (i.e., BlanklO, Blank_40, Free_10 and 
Free_40, with n=8 per group) were implanted without any complications or abnormal 
behavior in the animals. Three out of eight of the animals receiving composite scaffolds 
from Group P-AEPZ_10 experienced seizures in the immediate postoperative period. 
Two out of three of these animals were euthanized upon the recommendation of the 
consulting veterinarian. To continue the study, the animal protocol was modified and 
approved to include a preoperative intraperitoneal injection of fosphenytoin (60 mg/kg) 
30 minutes before surgery for the remaining animals implanted with composite scaffolds 
from Groups P-AEPZ10 (to replace the euthanized animals), P-AEPZ40, P-DED10 
and P-DED40. Each animal also received intraperitoneal injections of fosphenytoin at 
12 (20 mg/kg), 24 (20 mg/kg) and 36 (15 mg/kg) hours after surgery for maintenance. 
Some of the animals receiving a composite scaffold containing P-AEPZ (i.e., from 
Groups P-AEPZ_10 and P-AEPZ_40) and one animal receiving a composite scaffold 
containing P-DED (i.e. from Group P-DED10), which were given fosphenytoin before 
surgery, still experienced seizures. However, euthanasia was not recommended for these 
animals. Fosphenytoin was found to be capable of reducing the occurrence, severity and 
length of the seizures in this study and previous studies in both rats151 and humans . 
The animals were euthanized and implants were harvested at 12 weeks post-
implantation using a previously established method18. The resulting rectangular section, 
which included the defect site and implant, was placed into 10% neutral buffered 
formalin for 5 days and then placed into 70% ethanol. One of the animals implanted with 
a composite scaffold from Group P-AEPZ_40 had a large abdominal tumor that was 
discovered around 7 weeks post-implantation. The animal was euthanized upon the 
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recommendation of the consulting veterinarian prior to the end of the study and thus was 
not included in the microCT and histology evaluations. 
Microcomputed Tomography 
MicroCT was used to quantify the amount of bone formed within the defect. The 
retrieved samples were scanned, and the amount of bone volume in the defect was 
obtained as previously described18'138 with a global binarization threshold of 70-255. 
Maximum intensity projections (MIPs) for each sample were generated. An 8 mm 
diameter circular region of interest (ROI) was created in the MIP, and a binary image was 
obtained with a global binarization threshold of 70-255. The percent of area that was 
bone within the circular ROI was determined with the equation below. 
n, ^ Binarizedobject area , »„„, 
% Bone area = — x 100% 
ROI area 
The extent of bony bridging and union within the defect was also determined 
from the MIPs by two blinded observers (J.D.K and P.P.S.) separately according to the 
grading scale in Table V-2 as done previously18'138. A consensus score was obtained for 
each sample. 
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Table V-2 Scoring guide for extent of bony bridging and union obtained using maximum 
intensity projections of microCT datasets 
Description Score 
Bony bridging over entire span of defect at longest point (8 mm) 4 
Bony bridging over partial length of defect 3 
Bony bridging only at defect borders 2 
Few bony spicules dispersed throughout defect 1 
No bone formation within defect 0 
Histological Processing and Scoring 
After microCT scanning, the samples were dehydrated in a graded series of 
ethanol solutions (70% to 100%), followed by methylmethacrylate (MMA) embedding as 
done previously153. After polymerization, 5 [am thick coronal sections were prepared 
from the middle of the sample using a microtome. Three sections per sample were stained 
with hematoxylin and eosin (H&E). One section per sample was stained with Von 
Kossa/Van Gieson and one section per sample was stained with Goldner's Trichrome. 
The sections stained with H&E were quantitatively evaluated separately by three blinded 
observers (F.K.K., J.D.K. and P.P.S.) using light microscopy. The hard tissue response 
(1) at the scaffold-bone interface and (2) within the pores of the scaffold were evaluated 
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using the quantitative grading scale in Table V-3 as done previously18'138. A consensus 
score was obtained for each sample. 
Table V-3 Scoring guide for quantitative histological analysis 
Description Score 
Hard tissue response at scaffold-bone interface 
Direct bone to implant contact without soft interlayer 4 
Remodeling lacuna with osteoblasts and/or osteoclasts at surface 3 
Majority of implant is surrounded by fibrous tissue capsule 2 
Unorganized fibrous tissue (majority of tissue is not arranged as 
capsule) 
Inflammation marked by an abundance of inflammatory cells and 
poorly organized tissue 
Hard tissue response within the pores of the scaffold 
Tissue in pores is mostly bone 
Tissue in pores consists of some bone within mature, dense fibrous 
tissue and/or a few inflammatory response elements 
Tissue in pores is mostly immature fibrous tissue (with or without 
bone) with blood vessels and young fibroblasts invading the space 
with few macrophages present 
Tissue in pores consists mostly of inflammatory cells and connective 
tissue components in between (with of without bone) OR the majority 
of the pores are empty or filled with fluid 
Tissue in pores is dense and exclusively of inflammatory type (no 
bone present) 
1 
Statistical Methods 
For the results of the release kinetics of pDNA in vitro in the different phases, 
repeated measures analysis of variance (ANOVA) was used to identify if there were 
significant differences among groups at an alpha level of 0.05. Tukey-Kramer multiple 
I l l 
comparison test was then conducted to identify the specific groups that differed 
statistically significantly. For the cumulative release after 30 d in vitro and the microCT 
bone volume and area results obtained from the in vivo study, multi-factor ANOVA was 
used to identify if there were significant differences among groups at an alpha level of 
0.05. Tukey's Honestly Significantly Difference (HSD) test was then conducted to 
identify the specific groups that differed statistically significantly. For the microCT bone 
union and histology hard tissue response scoring results obtained from the in vivo study 
(discrete ordinal values), ordered logistic regression was used to identify if there were 
significant differences among groups at an alpha level of 0.05. An analysis of effects was 
then performed to identify the specific groups that differed statistically significantly. 
Results 
PPF Scaffolds Porosity and Interconnectivity 
The porosity of the PPF scaffolds was determined by microCT and mercury 
porosimetry and was found to be 64.3 ±1 .0 and 67.1 ± 0.8%, respectively, which is 
comparable to what was reported by Patel et al. for the same porous PPF scaffold 
formulation (~70%)18. More than 98.8 ± 0.3% of the pores in the scaffolds were 
connected to the outside environment through an opening of 32 urn or larger (Fig. V-l). 
Pores of at least 10 |j,m are needed for bone cell migration . The interconnectivity 
gradually decreased as the opening cut-off increased. 
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Figure V-l Pore interconnectivity obtained by microCT analysis at different minimum 
connection size. The results represent means ± standard deviations of n = 3. 
In Vitro Plasmid DNA Release Kinetics 
The in vitro release of pDNA from the composite scaffolds was evaluated in PBS 
containing a physiological amount of collagenase over 30 days. The pDNA release 
profiles are shown in Figure V-2. The amount of pDNA released was divided into four 
time segments as done in previous studies138'139'142'149 to facilitate the comparison of the 
release rates of the different groups: Phase 1 (the first 24 h), Phase 2 (days 1-3), Phase 3 
(days 3-17) and Phase 4 (days 17-30) (Table V-4). The type of GMP (10 or 40 mM) did 
not have an overall significant effect on the pDNA release kinetics. However, the type of 
TAPP (no polymer (i.e., delivered as naked pDNA), P-AEPZ or P-DED) did have an 
overall significant effect on the pDNA release kinetics (p < 0.0001). 
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Figure V-2 Profiles of percent cumulative pDNA released in vitro in PBS containing 
collagenase. The results represent means ± standard deviations of n = 4. 
Groups FreelO and Free_40 had a large burst release of pDNA (92.6 ±1.1 and 
88.9 ± 2.5% pDNA per day, respectively) in the first 24 h (Phase 1) and significantly 
lower release rates in the subsequent phases (0.1 to 2.6% per day). All other groups had 
significantly lower release rates in Phase 1 (10.7 to 16.6% per day) compared to Groups 
Free_10 and Free_40. Groups P-AEPZ_10 and P-AEPZ40 had significantly higher 
release rates in Phase 2 (31.7 ± 10.2 and 32.1 ± 9.2% per day, respectively) compared to 
the other groups (1.7 to 11.0% per day). Groups P-AEPZ10 and P-AEPZ40 released 
pDNA at significantly higher rates in Phase 2 compared to the other phases (0.3 to 14.1 
% per day). Groups P-DED_10 and P-DED40 released pDNA at significantly higher 
rates in Phase 1 (16.0 ± 1.6 and 19.0 ± 2.1% per day, respectively) and Phase 2 (9.4 ± 0.8 
and 11.1 ± 1.9% per day, respectively) compared to Phase 3 and 4 (1.3 to 2.0% per day). 
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Table V-4 Release kinetics of pDNA from composite scaffolds in four different phases. 
The results are expressed as means ± standard deviation (% release per day) for n = 4. 
Group 
FreelO 
Free_40 
P-AEPZJO 
P-AEPZ40 
P-DED10 
P-DED 40 
Phase 1 
(%/day) 
First 24 h 
92.6 ± 1.1 a'b 
88.9±2.5a 'b 
13.4±7.7b 
14.1±16.6b 
16.0±1.6C 
19.0±2.1b 
Phase 2 
(%/day) 
Days 1-3 
1.7 ±0.4 
2.6 ±0.9 
31.8 ± 10.2a'b 
33.0±6.2a'b 
9.4±0.8C 
l l . l ± 1 . 9 b 
Phase 3 
(% / day) 
Days 3-17 
0.1 ±0.0 
0.2 ±0.2 
1.0 ± 1.1 
0.6 ±0.1 
1.6 ±0.2 
2.0 ±0.2 
Phase 4 
(% / day) 
Day 17-30 
0.1 ±0.0 
0.1 ±0.0 
0.3 ±0.1 
0.4 ±0.3 
1.3 ±0.2 
1.6 ±0.2 
a
 represents statistically significant difference (p<0.05) between one group from all other 
groups excluding the group with the same TAPP treatment (i.e., FreelO and Free_40, P-
AEPZ10 and P A E P Z 4 0 , P-DED10 and P D E D 4 0 are not significantly different 
from each other) within the same phase. 
b
 represents statistically significant difference (p<0.05) between one phase from all other 
phases within the same group. 
c
 represents statistically significant difference (p<0.05) between one phase from Phase 3 
and 4 within the same group. 
Although no difference in release kinetics was observed for 10 and 40 mM GMPs, 
visual observation of the samples at the end of the release study demonstrated that there 
was more degradation of 10 mM GMPs compared to 40 mM GMPs, as expected. After 
30 days, almost all of the 10 mM GMPs in samples from Groups Free_10 and P-
AEPZ10 were degraded. However, samples from Group P-DED_10 still had some 10 
mM GMPs remaining in the sample tubes. For samples with 40 mM GMPs, there were 
still some GMPs remaining in all the sample tubes. However, samples from Groups P-
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AEPZ40 and P-DED40 had a higher amount of 40 mM GMPs remaining in the sample 
tubes compared to samples from Group Free_40. 
In Vivo Bone Formation 
The ability of the composite scaffolds to induce bone formation was evaluated in 
a critical-size rat cranial defect over 12 weeks. 
MicroCT Analysis 
The percent of bone volume that formed in the defect was obtained by microCT 
(Fig. V-3A). Group Free_10 had significantly higher bone formation (5.0 ± 3.4%) 
compared to Groups P-AEPZJO and P-AEPZ40 (0.7 ± 0.9% and 0.5 ± 0.7%, 
respectively). The amount of bone healing was also analyzed by comparing the percent of 
bone area in the MIPs that were obtained by microCT (Fig. V-3B). As observed for the 
bone volume results, Group Free_10 had a significantly higher amount of bone area (21.9 
± 15.7%) compared to Groups P-AEPZJO and P-AEPZ40 (5.0 ± 5.9 and 2.6 ± 3.0%, 
respectively). 
The MIPs were also used to evaluate the extent of bony bridging and union based 
on the guide shown in Table V-2, and the average scores are shown in Figure V-4A. 
Groups P-AEPZ10 and P-AEPZ_40 had average scores of around 1 (1.3 ± 0.9 and 0.9 ± 
0.9, respectively), whereas the other groups had scores closer to 2 (1.9 to 2.3). 
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Figure V-3 Percent bone (A) volume formed within an 8 mm diameter and 1.5 mm thick 
cylindrical VOI as measured by microCT and (B) area formed within an 8 mm diameter 
circular ROI of the MIPs as measured by microCT at 12 weeks. The results are expressed 
as means ± standard deviation for n = 7-9. * represents a statistically significant 
difference between groups (p<0.05). 
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Figure V-4 (A) Average bone union score within the defect as measured by assessing 
MIPs obtained by microCT at 12 weeks. The results are expressed as means ± standard 
deviation for n = 7-9. represents a statistically significant difference between one group 
from all other groups (p<0.05) excluding the group with the same TAPP treatment (i.e., 
P-AEPZ10 and P_AEPZ_40 are not significantly different from each other). * 
represents a statistically significant difference between groups (p<0.05). (B) Bone union 
score distribution. 
118 
The extent of bony bridging and union in Group P-AEPZ10 (1.3 ± 0.9) was significantly 
lower than Groups Blank_10 and Free_10 (2.0 ± 1.3 and 2.3 ± 1.0, respectively). The 
extent of bony bridging and union in Group P-AEPZ_40 (0.9 ± 0.9) was significantly 
lower than all the other groups (1.9 to 2.3), excluding Group P-AEPZ_10. 
Figure V-5 Representative images of MIPs of rat cranial defects obtained by microCT at 
12 weeks. (A) Group Blank_10: 6.0% bone volume, 25.6% bone area, bone score = 3. (B) 
Group Blank_40: 3.0% bone volume, 17.3% bone area, bone score = 2. (C) Group 
FreelO: 10.2% bone volume, 47.0% bone area, bone score = 3. (D) Group Free_40: 
2.9% bone volume, 15.6% bone area, bone score = 2. (E) Group P-AEPZ_10: 1.0% bone 
volume, 6.2% bone area, bone score = 1. (F) Group P-AEPZ40: 0.1% bone volume, 
0.1% bone area, bone score = 0. (G) Group P-DED10: 6.6% bone volume, 26.1% bone 
area, bone score = 2. (H) Group P-DED40: 5.8% bone volume, 19.3% bone area, bone 
score = 2. Bar represents 2 mm. 
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None of the samples had total union, which corresponds to a bone score of 4 (Fig. V-4B). 
All the groups had at least 1 sample with a bone score of 3, which signifies partial union, 
except Groups Free_40 (all samples had a score of 2), P-AEPZ10 and P-AEPZ40. The 
groups containing only GMPs, Pluronic F-127 and a PPF scaffold (without any drug 
loaded) in this study (i.e., Groups BlanklO and Blank_40) had comparable bone scores 
(2.0 ± 1.3 and 1.9 ± 1.0, respectively) to that observed by Patel et al. (Group BLANK, 2.0 
1 Q 
±1.1) . The bone that formed in the defects was mostly on the dural side of the cranium. 
The bone usually formed from the defect margins, and, in some of the animals, bone 
formed further towards the middle of the defect (Fig. V-5A and V-5C). 
Histological Analysis 
Histological analysis was performed on the samples to further investigate the 
tissue response to the implanted composite scaffolds. The scoring of the hard tissue 
response at the scaffold-bone interface and within the pores of the scaffolds was 
performed on the H&E sections based on the guide shown in Table V-3, and the average 
scores are shown in Figure V-6. Groups Free_40 and P-AEPZ_10 had significantly lower 
scaffold-bone interface and pore tissue scores compared to Groups Blank_l 0, Blank_40, 
FreelO, P-DED_10 and P-DED_40. Group P-AEPZ_40 had a significantly lower 
interface score compared to Groups BlanklO, Blank_40 and P-DED40 and a 
significantly lower pore tissue score compared to Groups Blank_40, P-DED_10 and P-
DED 40. 
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Figure V-6 Average histological scores for hard tissue response (A) at the scaffold-bone 
interface and (B) within the scaffold pores of the defect as assessed using H&E 
histological sections of rat cranial defects at 12 weeks. The results are expressed as 
means ± standard deviation for n = 7-9. Groups not connected with the same letter are 
significantly different from each other (p<0.05). 
All the groups had a majority of implants that were surrounded by a fibrous tissue 
capsule, which corresponds to a score of 2, except for samples from Groups P-AEPZ10 
and P-AEPZ_40 (Fig. V-7A). The implants from these groups were mostly surrounded by 
121 
unorganized fibrous tissue that was not arranged in a capsule, which corresponds to a 
score of 1. The pores of the implants were mostly filled with immature fibrous tissue with 
some blood vessel formation, which corresponds to a score of 2 (Fig. V-7B). Groups P-
AEPZ10 and P-AEPZ_40, however, had more samples where the majority of the 
implant pores were empty or filled with fluid which corresponds to a score of 1. 
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Figure V-7 Histological score distribution of hard tissue response (A) at the scaffold-
bone interface and (B) within the scaffold pores of the defect as assessed using H&E 
histological sections of rat cranial defects at 12 weeks. 
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One sample from Group Free _10 and two samples from Group Free_40 had implants 
with pores filled with dense inflammatory tissue, which corresponds to a score of 0. The 
interface of these implants was surrounded by an abundance of inflammatory cells and 
poorly organized tissue, which corresponds to an interface score of 0. 
Bone formation was mostly observed on the defect margin and on the outer 
surface of the implant (Fig. V-8A and V-8C) as confirmed with Von Kossa/Van Gieson 
staining, which stains mineralized tissue black. However, several samples also had bone 
formation in the pores of the scaffold (Fig. V-8H) and towards the middle of the defect. 
As observed by microCT, histological analysis also showed that the newly formed bone 
was mostly on the dural side of the defect (Fig. V-8A and V-8C). Minimal osteoid 
formation was observed in some samples as indicated by the dark red staining of the 
matrix by Goldner's Trichrome staining (shown in Supplementary Data). The osteoid 
matrix was observed mostly at the edge of the newly formed bone or the defect margin 
(i.e., host bone) and usually next to a line of osteoblasts arranged linearly along the 
developing bone. 
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Figure V-8 Representative histological sections of samples stained with Von Kossa/Van 
Gieson at 12 weeks (A) Group Blank_10, (B) Group Blank_40, (C) Group Free_10, (D) 
Group Free_40, (E) Group P-AEPZ_10, (F) Group P-AEPZ_40, (G) Group P-DED_10 
and (H) Group P-DED_40. P: PPF scaffold; B: new bone. Bar represents 500 jxm. 
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Discussion 
Porous PPF scaffolds have been used previously in our laboratory with GMPs to 
deliver BMP-2 in a controlled and sustained manner in a critical-size rat cranial 
defect18'138. In this work, we investigated the application of these composite scaffolds to 
deliver pDNA encoding BMP-2 complexed with biodegradable branched polycationic 
polymers, which we have previously characterized extensively108, and evaluated their 
ability to enhance bone formation in vivo compared to the delivery of naked pDNA from 
these composite scaffolds. 
In Vitro Plasmid DNA Release Kinetics 
In the first part of this work, the release kinetics of pDNA from the composite 
scaffolds were evaluated in vitro. In the first 24 h (Phase 1), there was a large burst 
release of pDNA from composite scaffolds that did not contain a TAPP (i.e., Groups 
FreelO and Free_40, 92.6 ± 1.1% and 88.9 ± 2.5% per day, respectively). The GMPs 
used in this study were synthesized from acidic gelatin and thus were negatively charged 
at physiological pH. Naked pDNA, which is also negatively charged due to the phosphate 
backbone, is not able to interact electrostatically with these GMPs, which results in 
inefficient loading of the GMPs with pDNA. Groups containing a TAPP (i.e., P-
AEPZ10, P-AEPZ_40, P-DED10 and P-DED40) only had a slight burst release in 
Phase 1, which could have resulted from the initial release of polypi exes not bound to the 
GMPs (10.7 to 14.7% per day). This initial burst release of unbounded drug in the first 24 
h has also been observed when growth factors were delivered from a similar composite 
scaffold138,139. The TAPP/pDNA polyplexes (300:1 weight ratio) have a net positive 
125 
1 OR 
charge , thus, are able to interact electrostatically with the negatively charged acidic 
GMPs. This results in a potentially stronger binding and more efficient loading of the 
pDNA to the GMPs. 
Following the initial burst release in Phase 1, the mechanism for the release of 
growth factors from these composite scaffolds is usually dominated by the enzymatic 
degradation of the GMPs 138>139. Although release of the drug from the GMPs by 
diffusion or dissociation through a change in environment (such as a change in ionic 
concentration) can occur, enzymatic degradation of the GMPs is the more likely 
mechanism for the drug release154. If the pDNA release mechanism from GMPs was the 
same as that observed previously with growth factors, the pDNA release would also be 
dominated by the degradation of the GMPs. In this study, we found that the GMP 
crosslinking density (which influences the degradation kinetics of the GMPs) did not 
affect the release profiles of the pDNA and that the pDNA release depended on the 
known degradation rates of the TAPPs instead. Thus, beyond the initial release of 
polyplexes not bound to the GMPs in Phase 1 and the minimal release of intact 
polyplexes through diffusion or dissociation, the remaining pDNA in polyplexes that 
were bounded to the GMPs were likely released from the composite scaffolds as naked 
pDNA or in polyplexes with a lower amount of polymer (i.e., lower polymer/pDNA 
weight ratio), as fragments of the polymer had to degrade to dislodge and release the 
pDNA from the GMPs. 
A previous in vitro degradation study in our laboratory has shown that -80% of 
the esters in P-AEPZ and P-DED degrade after 3 days and 14 days at pH 7.4, 
1 OX 
respectively . The actual amount of ester in the TAPPs that has to be degraded to lead 
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to release of the pDNA in the polypi exes is unknown. Nonetheless, it is hypothesized that 
the higher degradation rate of P-AEPZ compared to P-DED will cause polypi exes formed 
with P-AEPZ to have a higher pDNA release rate compared to those formed with P-DED. 
In Phase 2, the significantly higher pDNA release rate for Groups P-AEPZ_10 and P-
AEPZ40 compared to the other groups indicates that in 1 to 3 d, enough ester groups in 
P-AEPZ had degraded to result in a burst release of pDNA (31 to 32% per day). As 
suggested from the ester degradation rate of P-AEPZ (80% ester degraded after 3 d), a 
high amount of esters in P-AEPZ may be degraded during this phase, as well as in the 
following phases (i.e., Phase 3 and 4). Thus, the pDNA released from Groups P-
AEPZ_10 and P-AEPZ40 beyond Phase 1 were more likely naked pDNA or polypi exes 
with a lower amount of polymer (i.e, lower polymer/pDNA weight ratio). 
Compared to P-AEPZ, P-DED, which has a significantly lower degradation rate 
(80%o ester degraded after 14 d), should have a lower amount of esters that are degraded 
in Phase 2 and should not have reached the amount necessary to dislodge or release the 
pDNA from the polyplexes that are bound to the GMPs. Thus, unlike groups containing 
P-AEPZ (which released 31 to 32% per day), the significantly lower amount of pDNA 
released in Phase 2 by groups containing P-DED (9 to 10%> pDNA per day) should 
mostly be in the polyplex form, which could have been released through diffusion or 
dissociation of polyplexes that have less stable electrostatic interactions with the GMPs. 
However, at the later phases (i.e., Phase 3 and 4), the release of pDNA from composite 
scaffolds containing P-DED were more likely released as naked pDNA or pDNA with 
less fragments of polymer, as P-DED would have degraded enough to dislodge or release 
the encapsulated pDNA at these later time points. At the end of the study, almost the 
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entire loaded dose of pDNA (93 to 98%) from Groups FreelO, Free_40, P-AEPZ10 
and P-AEPZ_40 had been released, which was significantly higher than the amount of 
pDNA release from Groups P-DED_10 and P-DED40 (74-82%). Thus, there was likely 
more pDNA (18 to 26%, approximately 1/4 to 1/5 of the total loaded pDNA) remaining 
in the composite scaffolds from these groups that could potentially be released beyond 
the 30 day endpoint of the present study. Although the study design did not allow for the 
differentiation between pDNA of different extents of complexation (i.e., fully complexed, 
partially complexed and uncomplexed pDNA), the release data (free DNA detected after 
the 14 day incubation) coupled with the known TAPP degradation kinetics indicate that 
the pDNA release was dependent upon the TAPP degradation. The slower degradation 
rate of P-DED was able prevent the release of a large amount of pDNA too early during 
the delivery process and may also have been able to prolong the condensation and 
protection of the pDNA in the polyplexes. This is beneficial for the delivery of pDNA 
encoding BMP-2, as a later expression of BMP-2 is usually observed for osteoprogenitor 
cell differentiation in vitro155 and bone formation in vivo156. 
As opposed to the release of growth factors from GMPs ' ' ' , the enzymatic 
degradation rates of the GMPs did not significantly affect the pDNA release kinetics, 
although different GMPs degradation rates were observed. The TAPPs were degrading 
and releasing the pDNA faster than the GMPs were degrading and releasing the whole 
polyplexes. In this work, after 30 days, all the 10 mM GMP particles were degraded for 
the samples containing naked pDNA and polyplexes formed with P-AEPZ; however, they 
were not fully degraded for samples containing polyplexes formed with P-DED. The 
slower degradation rate of 10 mM GMPs in this study compared to the previous study 
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where they were completely degraded within 9 days142 suggests that the polyplexes may 
be shielding the GMPs from enzymatic degradation. The polyplexes formed with P-DED 
(i.e., TAPP with a lower degradation rate), which can stay attached to the GMPs for a 
longer time, were able to better shield the GMPs from degradation compared to 
polyplexes formed with P-AEPZ (i.e., TAPP with a higher degradation rate) and free 
pDNA. Although the release kinetics in vivo may differ from the results obtained in vitro, 
the in vitro analysis provides a predictive model and contextual data for the interpretation 
of the results from the in vivo bone formation study. 
In Vivo Bone Formation 
In the second part of this work, the ability of pDNA encoding BMP-2 complexed 
with a TAPP and delivered from a composite scaffold consisting of GMPs and a porous 
PPF scaffold to induce bone formation in a critical-size rat cranial defect was evaluated. 
We hypothesized that the delivery of pDNA complexed and condensed with a 
biodegradable polycationic polymer instead of in the free form (i.e., naked pDNA) would 
result in higher pDNA transfection and BMP-2 protein expression, which would be 
reflected by greater bone formation. However, the results from this study indicated that 
the addition of the biodegradable TAPP component to the delivery system did not 
improve the ability of the composite scaffolds to induce bone formation, even compared 
to composite scaffolds that did not contain pDNA (i.e., Groups Blank_10 and Blank_40) 
(Fig. V-3 and V-4). The reason for this observation is unclear as several factors are 
involved during the pDNA delivery as well as wound healing processes. We 
hypothesized that, even though a polycationic polymer vector component was 
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incorporated into the delivery system, the low amount of bone formation observed could 
have resulted from the unsuccessful delivery of most of the loaded pDNA in an intact 
polyplex form. As suggested from the results in the in vitro release kinetics study, 
excluding the initial burst release of unbound polyplexes and the minimal release of 
polyplexes through diffusion or dissociation from the GMPs, the pDNA released from 
these composite scaffolds was primarily naked pDNA or in polyplexes with a lower 
amount of polymer (i.e, lower polymer/pDNA weight ratio) which could have resulted 
from the degradation of the TAPPs. The release of the pDNA in the free or partially 
77 107 108 
complexed form at the defect site results in a decrease in transfection efficiency ' ' 
and increases the possibility of pDNA degradation by enzymes, nucleases157"159 and the 
low pH (~4) 5 in the wound healing environment. Even though the pDNA released from 
the composite scaffolds may have resulted in some BMP-2 protein production, the 
composite scaffolds in this study may have not delivered enough complexed and 
undegraded pDNA to allow for a sufficient amount and duration of protein expression to 
induce bone formation25'44. 
It is promising to see that some of the samples had bone growth even towards the 
middle and not just on the periphery of the defect. As seen by others in the literature who 
delivered BMP in the protein18 or gene77'106 form in a critical-size rat cranial defect, the 
bone that formed was mostly on the dural side of the cranium instead of on the periosteal 
side. The sagittal sinus of the rat runs in the center of the defect, under the dura mater, 
and could be a source of progenitor cells to the defect area106 which could have resulted 
in the higher amount of bone observed on the dural side. Histological evaluation 
demonstrated that a majority of the implants were surrounded by a thin layer of fibrous 
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tissue on the periosteal side and at the defect border between the implant and host bone. 
Some implants were also surrounded by a thin layer of fibrous tissue on the dural side. 
Compared to the other groups, Groups P-AEPZ10 and P-AEPZ40 had implants 
that were surrounded with less fibrous tissue on the dural side and had less tissue 
ingrowth in the pores of the implants (Fig. V-8E and V-8F, respectively) which was 
reflected in the hard tissue response score distribution (Fig. V-7B). The lower scores for 
hard tissue response for Groups P-AEPZ_10 and P-AEPZ_40 are consistent with the 
significantly lower percent bone formation (volume and area, Fig. V-3A and V-3B, 
respectively) and bone union score (Fig. V-4A) observed with microCT compared to 
some of the other groups. 
In general, among the samples that had a pore tissue score of 2 and 3, implants 
from Groups P-DED10 and P-DED_40 had comparably more tissue ingrowth where 
almost all the pores were filled with fibrous tissue (Fig. V-8G and V-8H, respectively). 
The higher amount of tissue ingrowth observed in Groups P-DED10 and P-DED40 
suggests that these groups may have enhanced the production of BMP-2, which has the 
capability of initiating the recruitment of cells to the defect site. As seen in the in vitro 
release study, groups containing P-DED (i.e. Groups P-DED10 and P-DED40) were 
able to prolong the release of pDNA and may also have delivered more of the pDNA in 
the intact polyplex form due to the slower degradation rate of P-DED; however the effect 
of polyplex release kinetics on bone formation remains unknown. 
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Conclusions 
In this work, pDNA complexed with biodegradable branched polymers were 
delivered from a composite containing acidic GMPs and a porous PPF scaffold. The in 
vitro results showed that the degradation rate of the polycationic polymers can control the 
pDNA release kinetics. The in vivo results showed that the premature degradation of 
polycationic polymers may trigger the release of naked pDNA with minimal effect on 
bone formation in a critical-size rat cranial defect. The collective results showed that the 
degradation rate of different polymers in a pDNA carrier would affect not only its 
delivery but most importantly its transfection capability and therapeutic effect in vivo. 
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Supplementary Data 
Supplementary Figure V-l Representative histological sections of samples stained with 
H&E at 12 weeks. (A) Group Blank_10, (B) Group Blank_40, (C) Group Free_10, (D) 
Group Free_40, (E) Group P-AEPZ_10, (F) Group P-AEPZ_40, (G) Group P-DED_10 
and (H) Group P-DED_40. P: PPF scaffold; B: new bone; Black arrows: GMP. Bar 
represents 500 \im. 
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Supplementary Figure V-2 Representative histological sections of samples stained with 
Goldner's Trichrome at 12 weeks. (A) Group Blank_10, (B) Group Blank_40, (C) Group 
Free_10, (D) Group Free_40, (E) Group P-AEPZ_10, (F) Group P-AEPZ_40, (G) Group 
P-DED_10 and (H) Group P-DED_40. P: PPF scaffold; B: new bone; Black arrows: 
osteoid. Bar represents 100 u.m. 
134 
CHAPTER VI 
OVERALL CONCLUSIONS 
In this work, biodegradable branched polycationic polymers were synthesized 
from different amine and triacrylate monomers by Michael addition polymerization to 
evaluate the effects of altering certain polymer properties on characteristics which are 
important for gene delivery. These biodegradable polycationic polymers were then 
incorporated into a composite scaffold carrier to evaluate these vectors in a bone tissue 
engineering system. 
In the first specific aim, the effects of the hydrophilic spacer lengths in the 
polymer on characteristics which are important for gene delivery were investigated by 
varying the triacrylate monomer used in the synthesis. We found that the incorporation of 
hydrophilic spacers resulted in high cell viability upon exposure to the polymer and 
increased the ester degradation rate of the polymer. This study demonstrated that 
hydrophilic spacers could be incorporated into polycationic polymers to reduce their 
cytotoxicity and enhance their degradability, which may facilitate the continued 
development of polymeric non-viral gene delivery vectors. 
In the second specific aim, the effects of the amine basicities in the polymer on 
characteristics which are important for gene delivery were investigated by varying the 
amine monomers used in the synthesis. We found that amines that dissociated above pH 
7.4 and were available for pDNA complexation, were a key parameter for effective 
pDNA condensation and transfection. This study indicated that one would need to 
investigate the amount of amines that dissociate in specific pH ranges relevant for 
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autocatalytic degradation, pDNA complexation and endosomal escape instead of only 
examining the total amount of amine in the polymer. 
In the third and last specific aim, the TAPP/pDNA polyplexes were incorporated 
into a composite containing GMPs and a porous PPF scaffold to develop a bone tissue 
engineering system with the ability to control the release of pDNA and enhance bone 
formation in vivo. We found that the pDNA release kinetics in vitro were not affected by 
the crosslmking density of the GMPs (which influences the degradation kinetics of the 
GMPs) but depended, instead, on the degradation rates of the TAPPs. Besides the initial 
loss of polyplexes not bound to the GMPs and the minimal release of polyplexes through 
diffusion or dissociation from the GMPs, the pDNA was likely released as naked pDNA 
or as part of an incomplete polyplex, following the degradation of fragments of the 
polycationic polymer. Furthermore, we found that composite scaffolds containing 
TAPP/pDNA polyplexes did not result in enhanced bone formation compared to those 
containing naked pDNA. The results suggested that the degradation rate of different 
polymers would affect not only pDNA delivery but most importantly its transfection 
capability and therapeutic effect in vivo. 
The biodegradable TAPPs evaluated in this work are promising candidates for 
non-viral gene delivery and the findings of this work can be used for the design of non-
viral vectors with tailored structural and degradative characteristics as needed for specific 
applications. This work demonstrated that the premature degradation of the polycationic 
polymers may lead to the early release of naked pDNA with minimal effect on bone 
formation in a defect site. Thus, a gene delivery system consisting of biodegradable 
polycationic polymers should be designed to release the pDNA in an intact polyplex form. 
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In designing a successful gene therapy system for bone tissue engineering, the 
gene delivery vector and the carrier for the polyplexes (i.e., scaffold or composite 
scaffold) are both important factors to take into consideration, and they have to be 
suitable for one another. To ensure that the polyplexes formed with the biodegradable 
polycationic polymers are released in an intact form, a composite which is able to protect 
the polycationic polymer from degradation before the pDNA is released should be 
considered. 
The polymers synthesized in this work have relatively low molecular weight (1 to 
3 kDa) and thus degrade faster compared to higher molecular weight polymers. 
Polyplexes formed with these low molecular weight polymers may be able to stay intact 
during the in vitro transfection process where the cells were directly exposed to the 
polyplexes. However, for in vitro or in vivo gene therapy approaches where the 
polyplexes are first released from a scaffold, the polyplexes may take a longer time to 
reach the cells. Thus, a slower degrading polymer may be needed for these gene therapy 
systems to ensure that the polyplexes stay intact during the delivery process. 
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